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ABSTRACT
THE ROLE OF YES-ASSOCIATED PROTEIN 1 IN
OVARIAN PHYSIOLOGY AND PATHOLOGY
Xiangmin Lv, Ph.D.
University of Nebraska, 2017
Supervisor: Cheng Wang, Ph.D.
Ovarian granulosa cells are the major somatic components of the ovarian follicle.
Proper proliferation and differentiation of ovarian granulosa cells are essential for
successful follicle development. Accumulating evidence indicates that the Hippo-YAP
signaling pathway plays critical roles in both development and tumorigenesis of several
organs. The present study aims to investigate the role of Yes-associated protein 1 (YAP)
in ovarian granulosa cell proliferation, differentiation, and malignant transformation. At
first, we found that nuclear YAP (active) was highly expressed in proliferative granulosa
cells, whereas cytoplasmic YAP (inactive) was detected mainly in terminally-differentiated
luteal cells. Further studies suggested that endogenous YAP activity is essential for
granulosa cell proliferation and survival to support follicle growth. However, overactive
YAP impaired differentiation and stimulated malignant transformation of granulosa cells,
indicating that YAP overactivation may play a role in the development of granulosa cell
tumors which come from failure of terminal differentiation of granulosa cells to luteal cells.
This idea was further supported by the overexpression of YAP detected in the human
granulosa cell tumor tissues and the critical role of YAP in the progression of granulosa
cell tumor.
High-grade serous ovarian cancer (HGSOC) is the most common and lethal type of
ovarian cancer. A novel mesenchymal subtype of HGSOC has been recently identified by
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both The Cancer Genome Atlas and Australian Ovarian Cancer Study studies and the
origin of this subtype has yet to be defined. Here, my studies show that YAP can induce
high-grade ovarian cancers with mesenchymal features from poorly differentiated
granulosa cells. In xenograft mouse models, overactive YAP elicits malignant ovarian
cancer development in the peritoneum of host mice from poorly differentiated human
granulosa cells. These tumors presented in mouse peritoneum as typical human HGSOC
morphologically, histologically, and genetically. However, these tumors overexpressed Ncadherin and vimentin but had low expression of CA125 and E-cadherin, features
reminiscent of the recently identified mesenchymal HGSOC. These studies suggest that
granulosa cells may be a cell-of-origin for the mesenchymal type of HGSOC.

v
TABLE OF CONTENTS
ACKNOWLEDGEMENTS ................................................................................................ I
ABSTRACT………………………………………………………………………………………III
TABLE OF CONTENTS ................................................................................................. V
LIST OF FIGURES ......................................................................................................... X
LIST OF TABLES ......................................................................................................... XII
LIST OF ABBREVIATIONS ......................................................................................... XIII
CHAPTER 1:YAP REGULATES PHYSIOLOGY OF GRANULOSA CELLS ................... 1
ABSTRACT .............................................................................................................. 2
1.1.

INTRODUCTION ....................................................................................... 3

1.1.1.

Ovarian granulosa cells ......................................................................... 3

1.1.2.

The Hippo-YAP pathway........................................................................ 3

1.1.3.

Yes-associated protein 1 (YAP) ............................................................. 4

1.1.4.

Previous research and present study ..................................................... 4

1.2.

MATERIALS AND METHODS ................................................................... 6

1.2.1.

Chemicals .............................................................................................. 6

1.2.2.

Immunohistochemistry and immunocytochemistry ................................. 6

1.2.3.

Cell collection and culture ...................................................................... 7

1.2.4.

YAP protein knockdown and overexpression ......................................... 8

1.2.5.

Three-dimensional hanging drop cell culture.......................................... 9

1.2.6.

Cell proliferation analysis ....................................................................... 9

1.2.7.

Apoptosis assays ..................................................................................10

1.2.8.

Enzyme-linked immunosorbent assay (ELISA) .....................................10

1.2.9.

Western blots ........................................................................................10

vi
1.2.10. Reverse transcriptase-polymerase chain reaction (RT-PCR) ................11
1.2.11. BODIPY staining ...................................................................................11
1.2.12. Colony formation assays.......................................................................12
1.2.13. In vitro ovary culture .............................................................................12
1.2.14. In vivo YAP inhibition ............................................................................13
1.2.15. Statistical analysis ................................................................................13
1.3.

RESULTS ................................................................................................14

1.3.1.

Expression of YAP in human and mouse ovaries..................................14

1.3.2.

YAP promotes proliferation and survival of human granulosa cells .......15

1.3.3.

YAP overexpression impairs steroidogenesis and cell differentiation ....16

1.3.4.

Overactive YAP induces dedifferentiation of granulosa cells .................17

1.3.5.

HBEGF stimulates YAP activity and granulosa cell proliferation ...........18

1.3.6.

Gonadotropin inhibits YAP activity and induces hormone production ....18

1.3.7.

YAP overactivation promotes granulosa cell growth in soft agar ...........19

1.3.8.

YAP inhibition results in defects of mouse follicle development ............20

1.4.

DISCUSSION ...........................................................................................21

1.4.1.

Overview...............................................................................................21

1.4.2.

YAP promotes granulosa cell proliferation and follicle growth ...............21

1.4.3.

YAP impairs GC differentiation .............................................................22

1.4.4.

Hippo-YAP signaling in follicle development .........................................23

1.4.5.

Conclusion ............................................................................................24

CHAPTER 2:YAP PROMOTES GRANULOSA CELL TUMOR PROGRESSION ...........42
ABSTRACT .............................................................................................................43
2.1.
2.1.1.

INTRODUCTION ......................................................................................44
The Hippo-YAP pathway in organ size control and tumorigenesis ........44

vii
2.1.2.

Etiology of granulosa cell tumor ............................................................45

2.1.3.

The present study .................................................................................46

2.2.

MATERIALS AND METHODS ..................................................................47

2.2.1.

Chemicals .............................................................................................47

2.2.2.

Cell lines and human GCT tissue slides ................................................47

2.2.3.

Immunohistochemistry analysis of YAP expression in ovarian tissues ..48

2.2.4.

Localization of YAP protein in KGN cells...............................................49

2.2.5.

YAP mRNA expression .........................................................................49

2.2.6.

Western blot analysis ............................................................................50

2.2.7.

Establishment of wild-type and mutant YAP overexpressed cell lines ...50

2.2.8.

Cell proliferation assay..........................................................................51

2.2.9.

Cell migration assay .............................................................................51

2.2.10. Statistical analysis ................................................................................52
2.3.

RESULTS ................................................................................................53

2.3.1.

Expression of YAP protein in GCT ........................................................53

2.3.2.

Expression of YAP in ovarian GCT tumor cell lines ...............................53

2.3.3.

Knockdown of YAP expression in KGN cells inhibits cell proliferation ...54

2.3.4.

Overexpression of YAP promotes KGN cell proliferation and migration 55

2.4.

DISCUSSION ...........................................................................................56

2.4.1.

Overview of previous studies and the present study on GCT ................56

2.4.2.

YAP expression in GCT and ovarian epithelial cancer ..........................57

2.4.3.

YAP promotes GCT progression ...........................................................58

2.4.4.

Conclusion ............................................................................................59

viii
CHAPTER 3:YAP INDUCES HIGH-GRADE OVARIAN CANCER WITH
MESENCHYMAL FEATURE FROM POORLY DIFFERENTIATED
GRANULOSA CELLS ...............................................................................70
ABSTRACT .............................................................................................................71
3.1.

INTRODUCTION ......................................................................................72

3.1.1.

High-grade serous ovarian cancer ........................................................72

3.1.2.

Origin of HGSOC ..................................................................................72

3.1.3.

Novel mesenchymal subtype of HGSOC ..............................................73

3.1.4.

Ovarian granulosa cells ........................................................................73

3.1.5.

Hippo-YAP signaling .............................................................................74

3.1.6.

Present study........................................................................................74

3.2.

MATERIALS AND METHODS ..................................................................75

3.2.1.

Cell culture............................................................................................75

3.2.2.

Retrovirus system for overexpression ...................................................75

3.2.3.

CRISPR Cas9 system to knockout BRCA1 ...........................................76

3.2.4.

Cell proliferation analyses .....................................................................76

3.2.5.

Western blot .........................................................................................76

3.2.6.

Three-dimensional hanging drop cell culture.........................................76

3.2.7.

Colony formation assays.......................................................................76

3.2.8.

Immunohistochemistry and immunocytochemistry ................................77

3.2.9.

Hematoxylin and eosin stain for histology analyses ..............................77

3.2.10. Alcian blue pH 2.5-periodic acid–Schiff stain ........................................77
3.2.11. Xenograft mouse model ........................................................................77
3.2.12. Array Comparative Genomic Hybridization (aCGH). .............................78
3.2.13. Statistical analysis ................................................................................78

ix
3.3.
3.3.1.

RESULTS ................................................................................................79
Overactive YAP induces malignant tumors from poorly differentiated
human granulosa cells .........................................................................79

3.3.2.

YAP overactivation induces malignant ovarian cancers like high-grade
serous ovarian cancer from granulosa cells .........................................80

3.3.3.

YAP induces high-grade ovarian cancers with mesenchymal features
from granulosa cells .............................................................................83

3.4.
3.4.1.

DISCUSSION ...........................................................................................84
YAP induces high-grade ovarian cancers from poorly differentiated
granulosa cells .....................................................................................84

3.4.2.

YAP elicits mesenchymal subtype of HGSOC from poorly differentiated
granulosa cells .....................................................................................85

3.4.3.

The genomic instability of HGSOC........................................................86

3.4.4.

Clinical significance ..............................................................................87

BIBLIOGRAPHY ..........................................................................................................104

x
LIST OF FIGURES
Figure 1-1. Expression of YAP and LATS1/2 in various stages of mouse ovarian follicles.
...................................................................................................................25
Figure 1-2. The expression of YAP with the development of ovarian follicles in human. 27
Figure 1-3. YAP promotes proliferation and supports survival of human granulosa cells.
...................................................................................................................29
Figure 1-4. YAP overactivation compromises cell steroidogenesis and impedes cell
differentiation ..............................................................................................32
Figure 1-5. YAP hyperactivation induces dedifferentiation of granulosa cells.................34
Figure 1-6. HBEGF and Gonadotropins regulate YAP activity and granulosa cell
proliferation and steroidogenesis.................................................................36
Figure 1-7. YAP promotes granulosa cell growth in soft agar. .......................................38
Figure 1-8. Inhibition of YAP disrupts ovarian follicle development in vitro and in vivo. ..40
Figure 2-1. YAP is expressed in human granulosa cell tumors (GCT). ..........................60
Figure 2-2. YAP is expressed in human ovarian GCT cell lines and epithelial ovarian
cancer cell lines. .........................................................................................62
Figure 2-3. YAP is required for KGN cell proliferation. ...................................................64
Figure 2-4. Overexpression of YAP stimulates KGN cell proliferation. ...........................66
Figure 2-5. YAP regulation of KGN cell migration. .........................................................68
Figure 3-1. YAP induces non-granulosa cell tumors from poorly differentiated granulosa
cells. ...........................................................................................................89
Figure 3-2. YAP induces malignant ovarian cancers from poorly differentiated granulosa
cells. ...........................................................................................................92
Figure 3-3. YAP elicits HGSOC-like tumors from poorly differentiated granulosa cells. .94

xi
Figure 3-4. YAP induces HGSOC-like tumors with mesenchymal features from poorly
differentiated granulosa cells.......................................................................96
Figure 3-5. Tumors derived from poorly differentiated granulosa cells genetically
resemble HGSOC. ......................................................................................98

xii
LIST OF TABLES
Table 1. Primers for PCR.............................................................................................100
Table 2. Antibodies ......................................................................................................102

xiii
LIST OF ABBREVIATIONS

3βHSD/HSD3B1

3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase
type I

aCGH

array comparative genomic hybridization

AOCS

Australian ovarian cancer study

AKT

AKT serine/threonine kinase

ANOVA

analysis of variance

AREG

amphiregulin

CYP19A1

cytochrome p450 family 19 subfamily a member 1

BRCA1

breast and ovarian cancer susceptibility protein 1

BSA

bovine serum albumin

CA125

mucin 16, cell surface associated

CDH1

Cadherin 1/E-Cadherin

CDH2

Cadherin 2/N-Cadherin

cGC

cumulus granulosa cells

CREB

cAMP responsive element binding protein 1

CTGF

connective tissue growth factor

DAPI

4’,6-diamidine-2’-phenylindole dihydrochloride

DMEM/F-12

Dulbecco’s modified eagle medium/nutrient mixture F-12

DMSO

dimethylsulfoxide

DNA

deoxyribonucleic acid

xiv
EGFR

epidermal growth factor receptor

ERBB

Erb-b2 receptor tyrosine kinase

ERK

extracellular signal-regulated kinase

FBS

fetal bovine serum

FSH

follicle stimulating hormone

FSHR

follicle stimulating hormone receptor

FSK

forskolin

GADPH

glyceraldehyde-3-phosphate dehydrogenase

GC

granulosa cell

GCT

granulosa cell tumor

H&E

hematoxylin and eosin

HBEGF

heparin binding EGF like growth factor

HGSOC

high-grade serous ovarian carcinoma

INHA

inhibin alpha subunit

INHBA

inhibin beta a subunit

INHBB

inhibin beta b subunit

JASP

jasplakinolide

Ki67

marker of proliferation Ki-67

KRT20

keratin 20

KRT7

keratin 7

LATS1

large tumor suppressor kinase 1

LATS2

large tumor suppressor kinase 2

xv
LC

luteal cell

LH

luteinizing hormone

LHCGR

luteinizing hormone/chorionic gonadotropin receptor

mGC

mural granulosa cell

MOB1

MOB kinase activator 1

mRNA

messenger ribonucleic acid

MST1

mammalian ste20-like protein kinase 1

MST2

mammalian ste20-like protein kinase 2

Myc

proto-oncogene c-myc

P450scc/CYP11A1

cholesterol side-chain cleavage enzyme,

p53

tumor protein p53

PAX2

paired box 2

PAX8

paired box 8

PBS

phosphate-buffered saline

PCR

polymerase chain reaction

PKA

protein kinase a

PLIN2

perilipin 2

PVDF

polyvinylidene difluoride

qPCR

quantitative real-time polymerase chain reaction

RT-PCR

reverse transcriptase polymerase chain reaction

SAV1

salvador homolog 1

S1P

sphingosine-1-phosphate

xvi
SNP

single-nucleotide polymorphism

TAZ

WW domain containing transcription regulator 1

TCGA

the cancer genome atlas

TEAD

TEA domain transcription factor

TERT

telomerase reverse transcriptase

UNMC

University of Nebraska Medical Center

WT1

Wilms tumor 1

YAP

Yes-associated protein 1

1

CHAPTER 1: YAP REGULATES PHYSIOLOGY OF GRANULOSA CELLS*

*

The material presented in this chapter was submitted as a manuscript: Lv et al. 2017.
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ABSTRACT
Ovarian granulosa cells are the major somatic components of the ovarian follicle, and
proper granulosa cell proliferation and differentiation are critical for normal follicle
development. Recent studies suggest that the Hippo-YAP pathway controls the
development of several organs; however, its role in ovarian follicle development remains
largely unknown. The present study investigates the role of YAP in ovarian granulosa cell
physiology. Immunohistochemical analyses showed that nuclear YAP was highly
expressed in proliferative granulosa cells, whereas cytoplasmic YAP was mainly detected
in terminally differentiated luteal cells, indicating that YAP activity may be involved in the
regulation of proliferation and differentiation of ovarian granulosa cells. YAP inhibition by
siRNA or pharmacological antagonist in human granulosa cells suppressed cell
proliferation, and overexpression of wild-type or constitutively active YAP impaired
gonadotropin-induced differentiation and stimulated rapid proliferation and malignant
transformation of granulosa cells. Cell signaling studies suggested that HBEGF, which
upregulated by YAP, activated YAP and promoted proliferation of granulosa cells.
Conversely, gonadotropin-activated PKA signaling inhibited YAP activity and stimulated
differentiation. Ovary in vitro culture experiments demonstrated that YAP inhibition
blocked growth of pre-antral ovarian follicles to antral follicles by suppressing granulosa
cell proliferation. Further, injection of Verteporfin (a selective antagonist of YAP) into
female CD1 mice inhibited disrupted mouse ovarian follicle development in vivo. Our
studies demonstrate that dynamic regulation of YAP activity is essential for granulosa cell
proliferation and differentiation to support ovarian follicle development.
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1.1.

INTRODUCTION

1.1.1. Ovarian granulosa cells
The ovary is a complex organ essential for producing oocytes and secreting steroid
hormones to achieve reproduction and maintain women’s health. The follicle is the basic
functional unit of the ovary. Ovarian granulosa cells, which contribute to most of the
somatic components of the ovarian follicle, can produce sex hormones and growth factors
for follicle development (1). After a fast-growth phase in undifferentiated status, granulosa
cells undergo differentiation under induction of the follicle stimulating hormone (FSH).
Transgenic mouse models demonstrated that FSH-deficient females became infertile due
to failure of antral follicle development, indicating the significance of gonadotropin-induced
granulosa cell differentiation during follicle development (2). Under the stimulation of
luteinizing hormone (LH), ovulation occurs, and granulosa cells exit the cell cycle and
terminally differentiate to luteal cells for progesterone production (3). Therefore, it is
essential that granulosa cells are coordinately regulated to proliferate and differentiate for
follicle growth and maturation to maintain normal ovarian function.
1.1.2. The Hippo-YAP pathway
Recent studies suggest that the Hippo-YAP pathway controls organ development (47). The Hippo-YAP pathway was first discovered in Drosophila and later found to be
conserved in mammals. The core components of the Hippo-YAP pathway in mammals
consist of the serine/threonine kinases Mammalian STE20-like protein kinase 1/2
(MST1/2) and Large Tumor Suppressor kinase 1/2 (LATS1/2), the scaffold proteins
Salvador homolog 1 (Sav1) and MOB kinase activator 1 (MOB1), and the downstream
transcriptional coactivators Yes associated protein 1 (YAP) and WW Domain Containing
Transcription Regulator 1 (WWTR1 or TAZ). Activation of upstream kinases by
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phosphorylation leads to subsequent phosphorylation of YAP and TAZ proteins, which
retains them in the cytoplasm and inhibits their transcriptional activity (4, 7, 8). Without
inhibition from upstream kinases, non-phosphorylated YAP and TAZ translocate into the
nucleus to bind with transcriptional factors such as TEA Domain Transcription Factor
(TEAD) to activate targeting gene expression to promote cell proliferation, survival, and
stem cell function.
1.1.3. Yes-associated protein 1 (YAP)
Extensive studies have recently indicated that YAP is a proto-oncogene that plays
important roles in organ growth and tumorigenesis by regulating cell proliferation and
apoptosis (6, 9-12). It has also been shown that YAP activity is involved in the regulation
of cell fate in the liver, lung, intestine and skin (13-21). For example, Hippo pathway
activation regulates maintenance of the differentiated hepatocyte state, whereas
increased YAP activity defines hepatic progenitor identity, driving liver overgrowth and
tumorigenesis (22). Furthermore, our previous report showed that YAP expression is
elevated in the granulosa cell tumor (GCT) compared with normal ovaries and that YAP
can promote GCT cell proliferation and migration (23).
1.1.4. Previous research and present study
Although many reports have focused on the Hippo pathway in the last decade, its role
in the development of mammalian ovarian follicle remains unclear. Studies from
Kawamura et.al. showed that fragmentation of ovaries stimulates follicle growth through
disruption of the Hippo-YAP pathway (24). Cheng et.al. recently showed that
Jasplakinolide (JASP) and sphingosine-1-phosphate (S1P) can stimulate follicle growth
by activating YAP protein (25). However, the cell types involved in these processes and
the underlying molecular mechanisms are not known. A recent study indicated that YAP
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is dispensable for oocyte survival, growth, and maturation in mouse model (26). Thus, the
present study focuses on the roles of YAP in regulation of granulosa cell physiology. Our
results indicate that the dynamic regulation of YAP activity is vital for granulosa cell
proliferation and differentiation to support ovarian follicle development for female fertility.
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1.2.

MATERIALS AND METHODS

1.2.1.

Chemicals

DMEM/F12 and other cell culture media were purchased from Sigma-Aldrich (St.
Louis, MO); fetal bovine serum (FBS) was from Atlanta Biologicals, Inc. (Lawrenceville,
GA); Alexa-conjugated secondary antibodies were from Life Technologies (Grand Island,
NY); YAP siRNA#1 and siRNA#2 were from Dhamarcon/Thermo Scientific (Pittsburgh,
PA); RNeasy Mini Kit was from QIAGEN Inc. (Valencia, CA); PCR reagents were from
Invitrogen (Carlsbad, CA), QIAGEN (Carlsbad, CA) or Bio-Rad (Hercules, CA);
Peroxidase-conjugated secondary antibodies for Western blotting were from Jackson
Immunoresearch Laboratories Inc. (West Grove, PA); the SuperSignal West Femto
Chemiluminescent Substrate Kit was from Pierce/Thermo Scientific (Rockford, IL); and
the Optitran® Nitrocellular transfer membrane was from Schleicher&Schuell Bioscience
(Dassel, Germany).
1.2.2. Immunohistochemistry and immunocytochemistry
Fluorescent immunohistochemistry was used to detect expression of YAP, Ki67, 3βHSD, and cleaved caspase-3 protein in the mouse ovary or the spheroids of 3D culture
system. Briefly, tissues were frozen in Tissue-Tek optimal cutting temperature (O.C.T.)
compound (Sakura Finetek Europe B.V., Flemingweg, AJ Alphen aan den Rijn, The
Netherlands). The blocks were sectioned at 6 µm thickness using a Leica CM3050S
instrument and attached to silane-coated slides. The frozen sections were fixed in freshly
prepared 4% paraformaldehyde and stained using antibodies for YAP, Ki67, 3β-HSD, and
cleaved caspase 3 protein overnight. Sections were then incubated with the appropriate
fluorescein-labeled (red or green) secondary antibody at room temperature for 30 min in
a humidified chamber. F-actin was stained with Rhodamine Phalloidin and nuclei were
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labeled with DAPI. Slides were mounted with Fluoromount-G (Southern Biotech,
Birmingham, AL) and coverslips. Images were captured using a Zeiss 710 Meta Confocal
Laser Scanning Microscope and analyzed using Zeiss Zen 2010 software (Carl Zeiss
Microscopy, LLC, Thornwood, NY).
YAP, LATS1, and LATS2 expression in paraffin-embedded human ovarian tissues
was detected using a peroxidase-based immunohistochemistry assay (VECTASTAIN
Elite ABC HRP kit, Vector Laboratories) and immunosignals were visualized with a DAB
kit (ImmPACT DAB Peroxidas HRP Substrate, Vector Laboratories). Stained sections
were counterstained with hematoxylin and covered with coverslips using Sakura
Automated Slide Stainer and Coverslipper. In negative controls, the primary antibody was
replaced by a blocking buffer containing the same amount of IgG from non-immune rabbit
serum. The sections were scanned with an iSCAN Coreo Slide Scaner (Ventana Medical
Systems, Inc., Oro Valley, AZ). Paraffin-embedded normal human ovarian tissue slides
were obtained from the Department of Pathology, Tianjin Medical University Cancer
Hospital and University of Nebraska Medical Center (UNMC). These human tissue slides
were used according to protocols approved by the UNMC Institutional Review Board and
Tianjin Medical University Institutional Review Board.
Fluorescent immunocytochemistry was used to localize YAP protein in KGN cells.
Briefly, cells were cultured on the coverslips. After treatments, cells were fixed in freshly
prepared 4% paraformaldehyde and stained for YAP protein as fluorescent
immunohistochemistry.
1.2.3. Cell collection and culture
Primary human granulosa cells were collected from follicular aspirates of reproductiveage patients during oocyte retrieval for in vitro fertilization (IVF) at the Heartland Center
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for Reproductive Medicine (Omaha, NE). Patients were treated with recombinant human
follicle stimulating hormone (FSH), followed by administration of hCG to induce follicle
development. After hCG treatment for 35 h, oocyte and follicular fluid were retrieved under
guidance by ultrasound. The oocyte and cumulus cells were collected for IVF. The
remaining follicular aspirates were held on ice and sent to the laboratory for studies. The
aspirates donated from a single patient were pooled and centrifuged at 500 g for 5 min.
Cells were resuspended in DMEM/F12 (Fisher Scientific Inc. Pittsburgh, PA) containing
2% penicillin-streptomycin. The cell suspension was then carefully layered onto 50%
Percoll, and centrifuged at 800 × g for 15 min. Granulosa cells were harvested from the
interphase of the medium and Percoll. After being washed 3 times with DMEM/F12,
granulosa cells were seeded into 10 cm dishes with DMEM/F12 containing 1% Ultroser G
serum substitute (Pall Corporation, Saint-Germain-en-Laye Cedex, France) and 1%
penicillin-streptomycin. The following day, granulosa cells were trypsinized and plated into
6-well plate for siRNA transfection or virus infection.
The HGrC1 and KGN cell lines were purchased from the Riken Biosource Center
(Riken Cell Bank, Tsukuba, Japan) and has been validated by short tandem repeat
polymorphism analysis. Cells were cultured in DMEM/F12 with the addition of 1% Ultroser
G serum substitute and 1% penicillin-streptomycin. Cells were incubated at 37 °C, 5%
CO2, and 95% air.
1.2.4. YAP protein knockdown and overexpression
YAP protein knockdown was performed with YAP targeting siRNA#1 and siRNA#2
(GE Darmacon, Lafayette, CO). Lipofactamine@ RNAiMAX Transfection Reagent (Grand
Island, NY) was used to deliver siRNA into cells according to manufacturer instructions.
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Using retrovirus-based YAP overexpression constructs given by Dr. Jixin Dong
(University of Nebraska Medical Center), hGC-YAP, and hGC-YAPS127A cells were
established with overexpression of wild-type YAP and constitutively active mutant YAP in
primary human granulosa cells (hGC), respectively. hGC-MX cells were established as
control with transfection of empty vector. Mutated YAP protein (S to A at residue 127)
prevents YAP from being phosphorylated at residue 127, resulting in constitutive
activation. Primary human granulosa cells were plated and cultured at 30 – 40%
confluence in 6-well plates, retrovirus with MX, YAP, and YAPS127A vectors were incubated
with cells overnight. After 72 h infection, positive cells were selected with G-418 (400
μg/ml) for 7 days.
1.2.5. Three-dimensional hanging drop cell culture
A three-dimensional (3D) hanging drop culture system was employed to mimic
granulosa cell growth in vivo. Briefly, an equal number (0.5 × 106) of hGC-MX, hGC-YAP,
and hGC-YAPS127A cells was loaded

onto a GravityPLUS™ 3D Cell Culture plate

(InSphero, Schlieren, Switzerland) according to manufacturer instructions. Culture
medium was replaced everyday and and the spheroids were culured at 37 °C, 5% CO2,
and 95% air for 7 days. Spheroids were imaged by an Olympus inverted microscopy
(Olympus America, Inc. Center Valley, PA). The volume of spheroids ((shortest diameter)2
× (longest diameter) × 3.14 /6) were calculated as indication of cell growth. The spheroids
were then embeded in OCT for preparation of frozen sections.
1.2.6. Cell proliferation analysis
Cell numbers were monitored with an Invitrogen Countess automated cell counter after
YAP knocked down or YAP/YAPS127A overexpressed for indicated time with proper
controls. Trypan blue was used to identify and quantify viable cells.
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1.2.7. Apoptosis assays
Cell apoptosis was monitored by an Annexin V-FITC Apoptosis Detection Kit
(BioVision Inc., San Francisco, CA) following manufacturer instructions. Briefly, after
indicated treatments, cells were trypsinized and incubated with Annexin V-FITC and
propidium iodide for 5 min. Flow cytometry was performed by the Flow Cytometry
Research Facility at the University of Nebraska Medical Center to monitor apoptosis.
1.2.8. Enzyme-linked immunosorbent assay (ELISA)
Estradiol and progesterone levels in cell culture media and mouse serum were
detected using ELISA assays. Medium estradiol levels were monitored using 17βEstradiol Enzyme Immunoassay Kit (Arbor Assays, Ann Arbor, Michigan). Progesterone
production was detected by using Progesteron(e) ELISA kit (DRG International Inc.,
Springfield, NJ).
1.2.9. Western blots
Cells were harvested on ice with ice-cold cell lysis buffer (10 mM Tris pH (7.4), 100
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 1% Triton x-100, 10%
glycerol, 0.1% SDS, and 0.5% deoxycholate, plus protease and phosphatase inhibitor
cocktails (Pierce/Thermo Scientific, Rockford, IL)). Each lysate was then sonicated for 3
s. Lysates were centrifuged at 18,350 x g for 15 min at 4 °C and supernatants were
collected for SDS-PAGE analysis. Protein concentration was determined by Bradford
assay (Bio-Rad 500-0006). Protein samples (30 µg) were loaded with protein-loading
buffer (50 mM Tris pH 6.8, 300 mM glycerol, 25 mM SDS, 45 mM DTT, 260 mM 2mercaptoethanol, and bromophenol) on 10% SDS-PAGE gel and separated by
electrophoresis. Separated proteins were then transferred to nitrocellulose membranes,
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which were blocked with 5% BSA in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween
20; pH 7.5) for 1 h at room temperature. Primary antibodies diluted in TBST with 5% BSA
were incubated with blocked membranes overnight at 4 °C or for 2 h at room temperature.
After washing 3 times with TBST for 5 min, membranes were further probed with antirabbit or anti-mouse HRP-conjugated IgG diluted in TBST with 5% BSA (1: 2,000) for 1 h
at room temperature. After washing 3 times with TBST for 5 min, protein bands were
detected with Thermo Scientific SuperSignal West Femto Chemiluminescent Substrate
Kit. Images were captured and analyzed with a UVP gel documentation system (UVP,
Upland, CA).
1.2.10. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was isolated from indicated cell cultures using the RNeasy mini kit (Qiagen,
Inc.) according to manufacturer instructions. First-strand cDNA was synthesized from 1
µg total RNA using iScript Reverse Transcription Supermix for RT-qPCR kit (Bio-Rad).
Quantitative RT-PCR was performed with gene-specific primers and iTaq Univerisal SYBR
green supermix by using CFX96 Real-Time System (Bio-Rad). GAPDH was used as
normalized control. RT-PCR was performed with GoTaq Flexi DNA Polymerase (Bio-Rad).
Products were loaded onto an agarose gel and separated by electrophoresis. Images
were captured by UVP gel documentation system.
1.2.11. BODIPY staining
Fluorescent neutral lipid dye 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-sindacene (BODIPY 493/503, green) was used to stain lipid droplets. Cells or frozen tissues
on slides were fixed with 4% paraformaldehyde and washed with PBS for 3 x 5 min.
BODIPY, Rhodamine Phalloidin, and DAPI diluted in normal donkey serum were
incubated with tissues/cells for 30 min. After three 5 min washes, slides were mounted
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with Fluoromount-G and coverslips. Pictures were captured by Zeiss 710 Meta Confocal
laser scanning microscopy.
1.2.12. Colony formation assays
The role of YAP in transformation was determined using a Cytoselect 96-Well Cell
Transformation assay kit (Cell Biolabs, Inc., San Diego, CA) according to manufacturer
instructions. Briefly, equal numbers of cells from diverse groups were plated in 0.6% soft
agar condition and cultured with treatments for 10 days. MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) was used to stain colonies, which were then imaged
and counted.
1.2.13. In vitro ovary culture
Mouse ovaries were collected at day 12 after birth. Ovaries were excised from the
ovarian bursa and transferred with a drop of medium onto Costar Transwell membrane
(non-tissue culture treated, Nucleopore polycarbonate membrane, 3.0-μm pore size, 24well insert). About one half ml of medium (Waymouth medium MB752/1 supplement with
0.23 mM pyruvic acid, 3 mg/ml BSA, 10% FBS, and 1% penicillin and streptomycin, 5
ng/ml FSH (Recombinant human FSH was obtained from National Institute of Diabetes
and Digestive and Kidney Diseases (Bethesda, MD)) was also added to support follicle
development) had been added in the well below the membrane insert. When the drop of
medium was add onto the membrane, the ovary was covered by only a thin film of medium.
The medium was changed every 2 days by adding 0.5 ml of medium to the chamber below
the membrane and then withdrawing the same volume. Cultures were incubated at 37 °C,
5% CO2, and 95% air for 7 d. Verteporfin or vehicle was added to medium for treatments.
At the end of experiments, ovaries were photographed and fixed. Histology and
immunohistochemistry were performed to exam the ovarian follicle development.
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1.2.14. In vivo YAP inhibition
Verteporfin (VP, 50 mg/kg) or vehicle (10% DMSO in PBS, 100 μl) was injected into
adult female CD-1 mice daily for 5 d. Ovaries and serum were collected for RNA, protein,
IHC, and TUNEL analyses according to approved ICAUC protocols.
1.2.15. Statistical analysis
All experiments were performed at least three times unless otherwise noted. The data
are presented as representative experiments or as the means ± SEM of the averages from
multiple experiments. Statistical analysis was conducted using GraphPad Prism software
(GraphPad Software, Inc. La Jolla, CA). Statistical comparisons between two groups were
analyzed for significance by two-tailed Student’s t-test. Multiple group comparisons were
assessed by one-way analysis of variance with Tukey’s post-Hoc test. P ≤ 0.05 was
considered statistically significant.
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1.3.

RESULTS

1.3.1. Expression of YAP in human and mouse ovaries
The spatio-temporal expression of YAP during ovarian follicle development in
mammals has not been thoroughly investigated. We monitored the expression level and
location of YAP in both mouse and human ovaries using immunohistochemistry.
Fluorescent immunohistochemistry analyses showed that the expression of YAP was
mainly located in the granulosa and luteal cells of the mouse ovary (Fig. 1-1 A1, B1 , C1 &
C0). In early granulosa cells of primary (P1) and secondary (P2) follicles, YAP was
moderately expressed in the nuclei (Fig. 1-1 A1). In the growing follicle, granulosa cells
are proliferative, as indicated by high expression of proliferation marker Ki67 (Fig. 1-1 A2,
B2 & C2). In granulosa cells of growing follicles, YAP protein was highly expressed in the
nuclei (Fig. 1-1 A1, B1, C1 & C0). However, when granulosa cells terminally differentiated
into luteal cells, which highly expressed 3βHSD enzyme (Fig. 1-1 A3, B3 & C3), YAP was
largely located to the cytoplasm (Fig. 1-1 A1, B1, C1 & C0), indicating inhibited YAP activity
(9). The expression of YAP decreased dramatically in the late phase of luteal cells (lLC)
which express less 3βHSD enzyme and undergo regression (Fig. 1-1 B1 & B3). In addition,
LATS1 and LATS2, the upstream suppressors of YAP in the Hippo pathway, were
detected with elevated expression in luteal cells compared with their expression in
granulosa cells, respectively (Fig. 1-1 D1 & D2).
A similar expression pattern was observed in human ovaries. YAP was mainly
expressed in the nuclei of granulosa cells of early stage follicles (Fig. 1-2). In the
differentiating granulosa cells of antral follicle, YAP expression was detected in both
cytoplasm and nuclei (Fig. 1-2). Consistently, YAP was mainly located in the cytoplasm of
luteal cells (Fig. 1-2). Interestingly, YAP expression was focused in the nuclei of cumulus
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granulosa cells (cGC), though YAP tends to disperse much more in the cytoplasm of mural
granulosa cells (mGC) (Fig. 1-2). Previous study suggested that cGC were enriched in
transcripts for cell proliferation and mGC were enriched in transcripts associated with cell
differentiation and steroidogenesis (27). Together, these results suggest that proliferative
granulosa cells express active YAP protein, whereas YAP activity is gradually suppressed
during the differentiation of granulosa cells to luteal cells. Thus, YAP may be critical in the
regulation of proliferation and differentiation of granulosa cells.
1.3.2. YAP promotes proliferation and survival of human granulosa cells
The co-localization of active YAP and Ki67 staining in granulosa cells (Fig. 1-1)
suggests that YAP may be critical for granulosa cell proliferation. Using YAP-targeting
siRNA#1 and siRNA#2, YAP expression was efficiently knocked down in primary human
granulosa cells (hGC) (Fig. 1-3 A), and cell proliferation was suppressed significantly after
knockdown for 5 d (Fig. 1-3 B). YAP inhibition with siRNA#1 and siRNA#2 dramatically
increased cell apoptosis (Fig. 1-3 C), indicating essential role of YAP to support granulosa
cell survival. Employing a retrovirus-based system, hGC were expressed with empty
vector (hGC-MX), wild-type YAP (hGC-YAP), or constitutively active YAP (hGC-YAPS127A,
Serine 127 site was mutated to Alanine to avoid inhibition by LATS1/2 phosphorylation (4,
10)) to investigate the effects of YAP overactivation in human granulosa cells. Western
blots showed that both hGC-YAP and hGC-YAPS127A cells expressed high level of YAP
(Fig. 1-3 D), indicating high efficiency of overexpression. Compared with high levels of
phosphorylated YAP (S127) in hGC-YAP, hGC-YAPS127A cells had much less
phosphorylated YAP (S127) expression, which is similar with that of control (Fig. 1-3 D).
These results demonstrated that in hGC-YAP cells, the Hippo pathway actively
suppressed, in some extent, overexpressed wild-type YAP, whereas hGC-YAPS127A cells
successfully expressed constitutively active YAPS127A protein avoiding phosphorylation
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and inhibition. Overexpression of both wild-type and constitutively active YAP significantly
increased the proliferation of hGC, with hGC-YAPS127A cells have the most cell number
(Fig. 1-3 E).
To mimic the growth of granulosa cells in vivo, we established a three-dimensional
(3D) hanging drop culture system in which cells form natural cell contacts to grow as
spheroid structure (1, 28). YAP overexpression significantly stimulated human granulosa
cell growth in 3D culture, indicated by the increased volume of the spheroids formed by
hGC-YAP and hGC-YAPS127A cells compared with control (Fig. 1-3 F). Further fluorescent
immunocytochemistry analyses showed that YAP overexpression increased Ki67 and
decreased cleaved Caspase 3 expression (Fig. 1-3 G & H). A pharmacological inhibitor
Verteporfin (VP), which specifically blocks YAP activity (29), reduced Ki67 and increased
cleaved Caspase 3 expression (Fig. 1-3 G & H). Taken together, YAP stimulates
proliferation and supports survival of human granulosa cells.
1.3.3. YAP overexpression impairs steroidogenesis and cell differentiation
The distinct expression pattern of YAP in granulosa cells and luteal cells suggests that
YAP activity may negatively regulate the differentiation of granulosa cells. Gonadotropinsinduced PKA pathway activation regulates the differentiation of granulosa cells (30, 31).
We utilized FSH and forskolin (FSK, an adenylate cyclase activator (32)) to induce
hormone production of hGC and KGN cells with different YAP activity (hGC-MX, hGCYAP, hGC-YAPS127A, KGN-MX, KGN-YAP, and KGN-YAPS127A). FSK or FSH treatments
induced hormone production in control cells as expected (Fig. 1-4 A & C). Overexpression
of YAP or YAPS127A decreased both the basal and FSK or FSH induced production of
estradiol and progesterone (Fig. 1-4 A & C). Interesting, YAP or YAPS127A overexpression
almost eliminated FSH induced hormone production (Fig. 1-4 C). Quantitative PCR results
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demonstrated that YAP overexpression reduced mRNA of steroidogenic enzymes
aromatase (CYP19A1) and cholesterol side-chain cleavage enzyme (P450scc/CYP11A1)
in granulosa cells with or without FSK treatment (Fig. 1-4 B). Western blot results further
demonstrated that overexpression of YAP or YAPS127A dramatically decreased FSH- and
FSK- induced expression of aromatase and P450scc (Fig. 1-4 D). These results indicate
that overactivation of YAP compromised steroidogenesis of human granulosa cells by
down-regulation of key enzymes.
Lipid droplet formation is a marker of granulosa cell differentiation (33, 34), BODIPY
staining showed numerous lipid droplets in the differentiated luteal cells but few in
granulosa cells (Fig. 1-4 E). FSK treatment induced mass production of lipid droplets in
control cells, indicating cell differentiation induced by FSK (Fig. 1-4 E). However,
overexpression of YAP or YAPS127A reduced the formation of lipid droplets under FSK
induction, suggesting that differentiation was impaired by YAP overactivation (Fig. 1-4 E).
1.3.4. Overactive YAP induces dedifferentiation of granulosa cells
To further investigate the role of YAP in cell differentiation, key molecules related to
granulosa cell differentiation were detected by Quantitative PCR. On the one hand, YAP
or YAPS127A overexpression significantly increased mRNA expression of Myc, and TERT
(Fig. 1-5 A), which are important molecules for retaining stemness and are enriched in
early granulosa cells and tumor cells (35, 36). On the other hand, overexpression of YAP
significantly decreased mRNA expression of FSHR, CYP19A1, CYP11A1, INHA, INHBA,
INHBB, and PLIN2, all of which are differentiation markers of granulosa cells (Fig. 1-5 A).
Together these results suggest that YAP hyperactivity induces dedifferentiation of
granulosa cells.
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Previous studies showed that YAP can promote epithelial cells to undergo epithelial–
mesenchymal transition (EMT) (37-39). However, our results showed hyperactive YAP
promotes mesenchymal–epithelial transition (MET) of granulosa cells by decreasing
mesenchymal proteins including vimentin, Snail, Slug, and by elevating epithelial markers
Claudin 1 and ZO-1 (Fig. 1-5 B). Recent studies suggested that MET is vital for cell
reprogramming (40, 41), support our idea that YAP reprograms granulosa cells to a
dedifferentiation status.
1.3.5. HBEGF stimulates YAP activity and granulosa cell proliferation
The epidermal growth factor (EGF) family plays significant role in granulosa cell
proliferation and differentiation during follicle development (42). A previous study showed
that HBEGF, a member of EGF family ligands, is expressed in the granulosa cells of earlystage follicle (43). We found that YAP upregulated HBEGF expression in granulosa cells
(Fig. 1-6 A). HBEGF stimulated granulosa cell proliferation, but suppressed production of
both estradiol and progesterone (Fig. 1-6 B). In turn, we found that HBEGF can activate
YAP in granulosa cells. Western blot results showed that HBEGF can dephosphorylate
YAP at S127 site following dephosphorylation of upstream LATS1 kinase (Fig. 1-6 C). The
phosphorylation of ERK and AKT were induced by HBEGF in 10 minutes, which occurred
before the dephosphorylation of YAP and LATS1. These results suggest that HBEGF
stimulates YAP activity and granulosa cell proliferation.
1.3.6. Gonadotropin inhibits YAP activity and induces hormone production
Then we ask how gonadotropin-induced differentiation signaling affects YAP activity.
Both FSH and FSK were able to induce cultured granulosa cell differentiation to produce
estradiol and progesterone (Fig. 1-6 D), whereas cell proliferation was suppressed (Fig.
1-6 D). Interestingly, we found that FSH and FSK increased YAP phosphorylation at S127
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site following elevated LATS1 phosphorylation (Fig. 1-6 E). The phosphorylation of CREB
indicated that differentiation PKA signaling pathway was activated by FSH and FSK as
expected (Fig. 1-6 E). Fluorescent immunocytochemistry results showed that the
cytoplasmic retention of YAP was increased under FSK treatment (Fig. 1-6 F). Further,
FSK can down regulated mRNA expression of HBEGF, which was upregulated by YAP
(Fig. 1-6 G). These results suggest that gonadotropin-induced PKA pathway activation
inhibits YAP activity and induces hormone production of granulosa cells.
1.3.7. YAP overactivation promotes granulosa cell growth in soft agar
Impairment of granulosa cell differentiation may result in uncontrolled proliferation and
thus malignant cell transformation (44). To examine the role of YAP in the transformation
of granulosa cells, in vitro soft agar assays were performed. Empty vector transfected
hGC-MX cells formed few or no large colonies in the soft agar culture after seeding for 10
d, whereas both wild-type (hGC-YAP) and constitutively active YAP (hGC-YAPS127A)
overexpressing granulosa cells formed many large colonies (Fig. 1-7 A & B). hGCYAPS127A cells formed the most colonies (Fig. 1-7 A & B). Pharmacological inhibition of
YAP by Verteporfin resulted in failure of colony formation in YAP or YAPS127A
overexpressing cells (Fig. 1-7 A & B), indicating that YAP may promote the transformation
of granulosa cells. To avoid potential subjective results from manual colony number
counting, fluorescence-based cell transformation assays were used to analyze cell growth
in the anchorage-independent culture. The results further demonstrated that YAP or
YAPS127A overexpression stimulated human granulosa cell growth in soft agar, whereas
inhibition of YAP activity reversed the anchorage-free growth induced by YAP
overactivation (Fig. 1-7 A & B).
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1.3.8. YAP inhibition results in defects of mouse follicle development
In vitro ovary culture system was used to examine the role of YAP for ovarian follicle
development. Mouse ovaries were collected at day 12 after birth and cultured on
membrane with or without addition of Verteporfin (VP). After culture in vitro for 7 d, ovaries
of control (CTL) group developed growth follicles which can be observed under
microscopy, whereas Verteporfin treated ovaries did not show follicle growth (Fig. 1-8 A).
Histological analyses showed antral follicles were formed in control ovaries, indicating that
in vitro-cultured ovaries keep the same pace of follicle development with in vivo condition
(Fig. 1-8 B). However, there is no antral follicle found in the Verteporfin treated group (Fig.
1-8 B). Further IHC analyses demonstrated that YAP inhibition blocked granulosa cell
proliferation and induced cell apoptosis, resulting in arrested follicle growth (Fig. 1-8 C &
D).
To further investigate inhibition of YAP effects on mouse follicle development in vivo,
intraperitoneal injection of Verteporfin (50 mg/kg, daily) or vehicle was conducted for 5 d.
Downstream YAP targeting genes Ctgf, Areg, Hbegf, Myc, and Erbb3 were downregulated
after Verteporfin treatment (Fig. 1-8 E), suggesting YAP activity was successfully blocked
by Verteporfin. TUNEL assay results evidenced increased apoptotic follicles in ovaries
after Verteporfin treatment (Fig. 1-8 F). Meanwhile, 3βHSD staining showed that the
number of corpus luteum were reduced with Verteporfin injection (Fig. 1-8 G), which was
also supported by decreased mRNA of Hsd3b (Fig. 1-8 H), a key enzyme expressed in
corpus luteum. Progesterone, secreted by the corpus luteum, was decreased in the blood
of Verteporfin treated mice compared with control group (Fig. 1-8 I). These results further
suggest that inhibition of YAP activity leads to defects of ovarian follicle development in
vivo.
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1.4.

DISCUSSION

1.4.1. Overview
Ovarian follicle development is vital for women’s fertility and health. Ovarian granulosa
cells are the major components of the follicle, contributing significantly to follicle growth
and oocyte maturation (1). In this study, we demonstrate that YAP, the key downstream
effector of the Hippo pathway, regulates granulosa cell proliferation and survival to support
follicle growth. However, overactivation of YAP impairs differentiation of granulosa cells,
leading to malignant transformation. Thus, our studies suggest that the orchestrated
regulation of YAP activity is critical for granulosa cell proliferation and differentiation to
support normal ovarian follicle development.
1.4.2. YAP promotes granulosa cell proliferation and follicle growth
Both fluorescent and chromogenic immunohistochemical analyses clearly showed that
a high level of nuclear-localized YAP was expressed in the rapid-proliferating granulosa
cells of mouse and human ovaries. These results suggest that YAP may play a key role
in promoting granulosa cell growth, thereby stimulating overall ovarian follicle growth.
Then we demonstrated that YAP is vital for granulosa cell proliferation and survival in vitro
using both traditional 2D culture and a novel 3D culture system. Utilizing Verteporfin to
block YAP activity, our in vitro ovary culture and in vivo mouse experiments further support
the vital role of YAP in granulosa cell proliferation to support follicle growth.
Previous studies showed that epidermal growth factor (EGF) family regulate granulosa
cell proliferation and differentiation during follicle development (42, 45). Our previous study
showed that TGFα promotes proliferation and migration of granulosa cell tumor cells via
EGFR signaling (46), which has been shown to interact with YAP to regulate cell
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proliferation (47-49). A previous study showed that HBEGF was expressed in early stage
granulosa cells (43). Here, our results showed that nuclear YAP was highly expressed in
proliferative granulosa cells. Overexpression of YAP upregulated HBEGF expression and
HBEGF stimulates granulosa cell proliferation. In turn, HBEGF can activate YAP via
inhibition of Hippo signaling component LATS1. Our previous studies suggested that YAP
interacts with ERBB signaling and FGFR signaling to promote ovarian cancer progression
(50, 51). ERBB signaling and FGFR signaling are also implicated in the development of
ovarian follicles (42, 52-55). Here our data indicate that Hippo-YAP signaling may interact
with HBEGF signaling to regulate granulosa cell proliferation and differentiation.
1.4.3. YAP impairs GC differentiation
In differentiated luteal cells, however, YAP was found largely in the cytoplasm, in which
its transcriptional activity was presumably suppressed (9, 10), indicating that inactivation
of YAP activity may be necessary for granulosa cell luteinization. In addition, LATS1 and
LATS2 expression were elevated in luteal cells compared with granulosa cells, supporting
that YAP activity may be suppressed by upstream Hippo signaling kinases during the
differentiation of granulosa cells to luteal cells. Our studies demonstrated that
overexpression of YAP impedes differentiation and induces dedifferentiation and
anchorage-free growth of granulosa cells, suggesting malignant cell transformation.
During ovarian follicle development, differentiation of granulosa cells was elicited by FSH,
while terminal differentiation of granulosa cells into non-dividing luteal cells is triggered
after ovulation by high levels of LH, where exit from the cell cycle is required to stop
division (3, 56). Protein Kinase A (PKA) mediates gonadotropin signals to induce
granulosa cell differentiation (57). Our results demonstrate that gonadotropin-induced
differentiation signals inactivate YAP by phosphorylation, resulting in proliferation arrest
and increase of hormone production. On the other hand, HBEGF, which activates YAP,
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stimulates proliferation and decreased hormone production of granulosa cells. The
presence of lower levels or lack of LH receptor in GCTs suggests that loss of LH
stimulation may lead to failure of granulosa cell luteinization, contributing to GCT formation
(44, 58). Our results showed that overactive YAP can suppress expression of
differentiation genes, resulting in failure of granulosa cell differentiation and uncontrolled
proliferation. However, the mechanism of suppressive effects of YAP on the expression
of differentiation genes need further studies.
1.4.4. Hippo-YAP signaling in follicle development
It is becoming clear that the Hippo signaling pathway constrains ovarian follicle growth
(1, 24). Previous studies showed that LATS1-null female mice presented a primary ovarian
insufficiency (POI) phenotype and developed ovarian tumors (59, 60), and LATS1
regulates the transcriptional activity of FOXL2, which is mutated in most of granulosa cell
tumor patients and some POI patients (61). In addition, Genome-wide association study
(GWAS) of polycystic ovary syndrome (PCOS) implicated YAP as a susceptibility gene for
PCOS (62). More importantly, recent studies in Dr. Hsueh’s lab shed lights on novel
therapy for PCOS by showing that temporary activation of YAP with physical
fragmentation or chemical treatments using JASP or S1P can promote ovarian follicle
growth (24, 25). The authors proposed that YAP activation in the whole ovary can
stimulate follicle development, however, the exact cell types involved in these process is
unclear. Our results demonstrate that YAP is vital for promoting growth and survival of
granulosa cells to support follicle growth, which provides the underlying mechanism of
why activation of YAP can stimulate follicle growth. Importantly, our study indicates that
granulosa cells may be the target cells for treating patients with defects of ovarian follicle
development. Recently, Yu et al demonstrated that YAP is dispensable for the survival,
growth and maturation of mouse oocytes (26), which further support our idea that
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granulosa cells are the targets of Hippo-YAP signaling regulation for follicle development.
However, hyperactivation of YAP impairs steroidogenesis and differentiation of granulosa
cells, leading to malignant transformation of granulosa cells. Taken together, our study
suggests that YAP activity should be dynamically regulated for granulosa cell proliferation
and differentiation to support follicle development and reminds us to be cautious and
meticulous when treating patients with ovarian failure by activation of YAP.
1.4.5. Conclusion
In conclusion, our data show that YAP is mainly expressed in the proliferative
granulosa cell nuclei and the cytoplasm of luteal cells. The YAP activity promotes
granulosa cell proliferation but prevents cell differentiation. HBEGF signaling activates
YAP and stimulate proliferation. On the other hand, gonadotropin-induced PKA activation
inhibits YAP activity and stimulate granulosa cell differentiation. YAP inhibition blocks
granulosa cell proliferation, resulting in arrested follicle growth and increased apoptotic
follicles. However, overactive YAP compromises cell differentiation and promotes
malignant transformation of granulosa cells. Therefore, the orchestrated regulation of YAP
activities is vital for granulosa cell physiology to support follicle development and ovarian
function.
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Figure 1-1. Expression of YAP and LATS1/2 in various stages of mouse ovarian
follicles.
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of YAP stain in C image. Actin was stained as rhodamine phalloidin (red) and nuclei were
stain by DAPI (blue). The chromogenic immunohistochemistry shows expression of
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LATS1 (D ) and LATS2 (D ) in the granulosa cells and luteal cells. (D , D ) are serial
paraffin sections. GC: granulosa cells; LC: luteal cells; lLC: late luteal cells; P1: primary
follicle; P2: secondary follicle. Bar: 50 μm.
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Figure 1-2. The expression of YAP with the development of ovarian follicles in
human.
The chromogenic immunohistochemistry shows YAP expression in human ovaries. P0:
primordial follicle; P1: primary follicle; P2: secondary follicle; GC: granulosa cells; cGC:
cumulus granulosa cells; mGC; mural granulosa cells; LC: luteal cells; SC: stromal cells;
TC: theca cells; O: oocyte; CTL: negative staining control. Bar: 100 μm.
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Figure 1-3. YAP promotes proliferation and supports survival of human granulosa
cells.
A) Western blots showing YAP protein knockdown with YAP-targeting siRNA#1 and
siRNA#2 for 5 d. β-Actin was used as loading control.
B) Representative pictures show growth suppression of hGC under YAP targeting siRNA
incubation for 5 d; the bar graph showing cell number counted 5 d after hGC cells were
transfected with control or YAP-targeting siRNA; scale bar: 200 μm.
C) YAP knockdown induces apoptosis of human granulosa cells: representative images
show Annexin V-FITC/propidium iodide double staining of hGC 5 d after transfection with
control or YAP siRNA; the bar graph showing quantitative data for the ratio of Annexin V
positive cells.
D) Western blots show YAP and phosphor-YAP (S127) expression in hGC-MX, hGC-YAP,
S127A

and hGC-YAP

cells, using β-Actin as loading control.

E) Representative images showing multilayer-growth of hGC after YAP overexpression;
bar graph showing cell number counting after plating for 5 d; scale bar: 200 μm.
F) Overexpression of YAP promotes human granulosa cell growth in a 3D culture system:
representative images showing the spheroids from hGC-MX, hGC-YAP, and hGCS127A

YAP

cells for 5 d; the bar graph showing quantitative data for the volume of spheroids;

scale bar: 500 μm.
G) Representative images showing Ki67 staining in spheroids formed by hGC-MX, and
S127A

hGC-YAP

cells with vehicle (DMSO, 0.1%) or Verteporfin (VP, 5 μM) treatment for 5

d; the bar graph showing quantitative data for the KI67 ratio; scale bar: 20 μm.
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H) Representative images showing cleaved caspase 3 (C-Cas 3) staining in spheroids
S127A

formed by hGC-MX, and hGC-YAP

cells with vehicle (DMSO, 0.1%) or Verteporfin

(VP, 5 μM) treatment for 5 d; the bar graph showing quantitative data for the cleaved
caspase 3 ratio; scale bar: 20 μm.
Each bar represents the mean ± SEM (n ≥ 4). Bars with different letters are significantly
different from each other (P < 0.05).
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Figure 1-4. YAP overactivation compromises cell steroidogenesis and impedes cell
differentiation
A) Overexpression of YAP or YAPS127A decreased base (CTL) and forskolin (FSK) induced
production of estrogen and progesterone in primary human granulosa cells.
B) Quantitative RT-PCR results show mRNA expression of CYP19A1 and CYP11A1 in
primary human granulosa cells with different YAP activity.
C) Overexpression of YAP or YAPS127A reduced base and FSH or FSK induced production
of estradiol and progesterone in KGN cells.
D) Western blot results show expression of key enzymes for steroidogenesis of KGN cells
with different YAP activity.
E) BODIPY staining showing lipid droplets distribution; upper panel: BODIPY staining
(green) showing the distribution of lipid droplets in mouse ovaries; lower panel: BODIPY
staining shows that YAP overexpression retarded FSK-induced lipid droplet formation;
scale bar = 50 um.
Each bar represents the mean ± SEM (n ≥ 4). When compared with control, *: P < 0.05,
**: P < 0.01, ***: P < 0.001.
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Figure 1-5. YAP hyperactivation induces dedifferentiation of granulosa cells.
S127A

A) mRNA expression of key molecules of differentiation in KGN cells with YAP or YAP

overexpression; each bar represents the mean ± SEM (n ≥ 3); when compared with control,
*: P < 0.05, **: P < 0.01, ***: P < 0.001.
B) Western blots showing the expression of proteins related to mesenchymal–epithelial
transition (MET) after YAP or YAP
control.

S127A

overexpression in KGN cells; β-Actin as loading
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Figure 1-6. HBEGF and Gonadotropins regulate YAP activity and granulosa cell
proliferation and steroidogenesis.
A) Overexpression of YAP upregulated HBEGF mRNA expression in hGC, HGrC1, and
KGN cells.
B) HBEGF treatment (50 ng/ml, 3 d) stimulated cell proliferation and suppressed
production of estradiol and progesterone.
C) Western blots showed that HBEGF (50 ng/ml) dephosphorylated YAP at S127 site
following LATS1 (S909) dephosphorylation; ρ-ERK and ρ-AKT were increased before
dephosphorylation of LATS1; β-Actin was used as loading control.
D) Bar graphs show the effects of FSH (50 ng/ml, 3 d) and forskolin (FSK, 10 μM, 3 d) on
the estrogen and progesterone production and cell proliferation.
E) Western blots showed that FSH (50 ng/ml) and FSK (10 μM) stimulate YAP
phosphorylation of S127 site following LATS1 (S909) phosphorylation; ρ-CREB was used
to show activation of PKA and β-Actin was used as loading control.
F) Forskolin (FSK) treatment (10 μM, 60’) increased YAP retention in the cytoplasm. Scale
bar = 20 μm.
G) Forskolin (FSK) treatment (10 μM, 3 d) decreased HBEGF mRNA expression.
Each bar represents the mean ± SEM (n ≥ 3). When compared with control (CTL), * means
P < 0.05; ** means P < 0.01; *** means P < 0.001.
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Figure 1-7. YAP promotes granulosa cell growth in soft agar.
A) Representative pictures showing colony formation in soft agar of hGC-MX, hGC-YAP,
S127A

and hGC-YAP

cells with or without Verteporfin (VP) incubation; scale bar: 500 um.

B) Bar graphs showing colony number counting and relative fluorescent unit (RFU) to
reflect viable cells in soft agar culture; each bar represents the mean ± SEM (n ≥ 4); when
compared with control, *: P < 0.05, **: P < 0.01, ***: P < 0.001.
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Figure 1-8. Inhibition of YAP disrupts ovarian follicle development in vitro and in
vivo.

A) Representative images showing morphology of d 12 mouse ovaries cultured for 7 d in
vitro with Verteporfin (VP) or not (CTL); scale bar: 500 μm.

B, C, D) Representative images showing H & E, Ki67, and cleaved Caspase 3 staining of
cultured mouse ovaries respectively; yellow arrows and cycles indicating antral follicles in
control group; scale bar: 50 μm.

E) Yap and targeting gene expression in the control and Verteporfin injected mouse
ovaries were detected with RT-PCR and western blots.

F) TUNEL assays show YAP inhibition increases the number of apoptotic follicles; scale
bar: 500 μm.
G) YAP inhibition decreases corpus luteum number; 3βHSD staining represent corpus
luteum location.
H) Bar graph showing the RNA expression of 3βHSD in control (CTL) and Verteporfin (VP)
injected mouse ovaries; scale bar: 500 μm.

I) YAP inhibition by Verteporfin (VP) decreases progesterone level of mouse serum.
Each bar represents the mean ± SEM (n ≥ 3). When compared with control (CTL), * means
P < 0.05; ** means P < 0.01; *** means P < 0.001.
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CHAPTER 2: YAP PROMOTES GRANULOSA CELL TUMOR
PROGRESSION†

†

The material presented in this chapter was previously published: Fu & Lv et al. EndocrineRelated Cancer 2014; 21(2):297-310.
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ABSTRACT
The Hippo signaling pathway has been implicated as a conserved regulator of organ
size in both drosophila and mammals. Yes-associated protein (YAP), the central
component of the Hippo signaling cascade, functions as an oncogene in several
malignancies. Ovarian granulosa cell tumors (GCT) are characterized by enlargement of
the ovary, excess production of estrogen, a high frequency of recurrence, and the potential
for malignancy and metastasis. Whether the Hippo pathway plays a role in the
pathogenesis of GCT is unknown. This study was conducted to examine the expression
of YAP in human adult GCT and to determine the role of YAP in the progression of GCT
cells. Compared with age-matched normal human ovaries, GCT tissues exhibited higher
levels of YAP expression. YAP protein was predominantly expressed in the nucleus of
tumor cells, whereas the non-tumor ovarian stromal cells expressed very low levels of
YAP. YAP was also expressed in cultured primary human granulosa cells and in KGN and
COV434 GCT cell lines. siRNA-mediated knockdown of YAP in KGN cells resulted in a
significant reduction in cell proliferation (P < 0.001). Conversely, overexpression of wild
type YAP or a constitutively active YAP (YAPS127A) mutant resulted in a significant increase
in KGN cell proliferation and migration. These results demonstrate that YAP plays an
important role in the regulation of GCT cell proliferation and migration. Targeting the
Hippo/YAP pathway may provide a novel therapeutic approach for GCT.
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2.1.

INTRODUCTION

2.1.1. The Hippo-YAP pathway in organ size control and tumorigenesis
The balance between cell growth and death plays a vital role in the maintenance of
tissue homeostasis, organ size, and normal biological functions of the human body. Under
physiological conditions, cell growth and apoptosis are tightly controlled. Aged or
damaged cells commit to programed cell death, whereas adult stem cells may divide and
differentiate to replace those dysfunctional cells to maintain tissue homeostasis and organ
size. Under pathological conditions, however, uncontrolled cell proliferation and
decreased cell death and/or differentiation can lead to hyperplasia or even tumorigenesis.
The mechanisms underlying the control of organ size are still largely unknown. Studies
have shown that the Hippo signaling pathway (Salvador/Warts/ Hippo pathway) plays a
critical role in controlling organ size by regulating both cell proliferation and apoptosis in
both Drosophila and mammals (8, 9, 63)
Yes-associated protein 1 (YAP1, also known as YAP) is the major downstream effector
of the Hippo pathway (64). The expression and role of YAP in cancer are cell-type- and/or
cellular-context-dependent (64, 65). Amplification of the YAP gene locus at 11q22 is found
in

hepatocellular

carcinoma,

breast

cancer,

oral

squamous

cell

carcinomas,

medulloblastomas, and esophageal squamous cell carcinomas (37, 66-69). In addition,
overexpression and nuclear localization of YAP protein are found in colon, liver, lung,
ovarian, and prostate cancers (8, 10, 67, 70). Moreover, overexpression of YAP leads to
oncogenic transformation of an immortalized epithelial cell line MCF10A (37). However,
YAP enhances p73-dependent cell death during cisplatin-induced DNA damage (65, 71),
indicating that YAP may interact with other pathways to optimize a tumor suppressor
response. In a subset of breast cancers, the expression of YAP protein was significantly
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decreased due to loss of heterozygosity, and short hairpin RNA (shRNA) knockdown of
YAP increased migration and invasiveness, and enhanced tumor growth (72). Therefore,
the expression and function of YAP in specific cancers requires further investigation.
2.1.2. Etiology of granulosa cell tumor
Granulosa cell tumors of ovary (GCT), accounting for 70% of malignant sex-cord
stromal tumors and 5–8% of all ovarian malignancies, are poorly understood ovarian
neoplasms (73). Patients with GCT have a high overall survival rate, which is mainly
attributed to diagnosis of GCT at an early stage. The prognosis is significantly poorer for
patients with advanced tumors. The 10-year survival rates in stage III and IV are lower
than 20% (74). Clinically, GCT have a propensity for late recurrence (75, 76).
Approximately, 80% of patients with advanced stage or recurrent tumors succumb to their
disease due to the limited treatment options for advanced and recurrent disease (73, 77).
These tumors also have malignant potential and metastatic ability. Indeed, metastases
from GCT have been reported in the lung, liver, brain, bone, diaphragm, abdominal wall,
pancreas, and adrenal gland (78).
Some factors and pathways have been shown to affect the development of GCT (73).
Importantly, recent studies have shown that a somatic mutation in FOXL2 (C402G) is a
potential driver in the pathogenesis of adult-type GCT (79-84). However, the exact
mechanisms underlying GCT progression, recurrence, and metastasis are largely
unknown. Oftentimes, GCT are hemorrhagic and manifest as painful abdominal masses,
with an average diameter more than 10 cm (74, 85-87). Occasionally, the diameter of the
GCT tumor can be over 30 cm (86, 88-90). This volume is several hundred-fold larger than
the regular human ovary, which is around 5 cm3. The significant increase in the volume of
the ovary indicates that the system controlling organ size in the patients with GCT is
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disrupted. As GCT are derived from ovarian granulosa cells, the proliferation of granulosa
cells in the patient’s ovary may be deregulated. However, the molecular pathology
underlying this remarkable increase in tissue size is unknown.
2.1.3. The present study
In this study, we compared YAP expression in normal human ovarian tissues and GCT
tissues using immunohistochemistry. YAP was also consistently detected in ovarian GCT
cell lines. We also examined the role of YAP in the regulation of GCT cell proliferation and
migration using the KGN human GCT cell line as a cellular model. Our results indicate
that the Hippo/YAP signaling pathway plays a critical role in the regulation of GCT
progression.
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2.2.

MATERIALS AND METHODS

2.2.1. Chemicals
Human FSH was from NHPP/NIDDK (Torrance, CA, USA). DMEM/F12 and other cell
culture medium were from Invitrogen. FBS was from Atlanta Biologicals, Inc.
(Lawrenceville, GA, USA). The Ribogreen RNA quantification kit and Alexa-conjugated
secondary antibodies were from Life Technologies Corp.; YAP small interfering RNA
(siRNA) was from Dhamarcon/Thermo Scientific (Pittsburgh, PA, USA). Secondary
antibodies for western blotting chemiluminescence were from Jackson Immunoresearch
Laboratories, Inc. (West Grove, PA, USA); PCR reagents were from Invitrogen, Qiagen or
Bio-Rad. All other molecular-grade chemicals were purchased from Sigma, Fisher
(Pittsburgh, PA, USA), or United States Biochemical (Cleveland, OH, USA).
2.2.2. Cell lines and human GCT tissue slides
The KGN cell line, an adult GCT cell line expressing a mutated FOXL2 (C402G) gene,
was obtained from the Riken BioSource Center (Riken Cell Bank, Ibaraki, Japan). The
COV434 cell line, a juvenile GCT cell line expressing wildtype FOXL2 gene, was received
from Dr. C E van der Minne (University Hospital, Leiden, The Netherlands). The SKOV-3
ovarian cancer cell line was purchased from the American Type Culture Collection (ATCC,
Manassas, VA, USA). The IGROV-1 ovarian cancer cell was received from Dr. Bo Reuda
(Massachusetts General Hospital, MA, USA). Human ovarian granulosa cells isolated
from two medium-sized follicles (5–10 mm in diameter) were obtained from a 33-year-old
patient who received oophorectomy for causes other than an ovarian disorder. The
collection of this tissue was permitted by a protocol approved by the University of
Nebraska Medical Center Institutional Review Board. The cells were isolated manually
with a needle and cultured in DMEM/F12 supplemented with 5% FBS. All cell lines used
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in this study were passaged fewer than ten times in our laboratories and were validated
for their authenticity by short tandem repeat (STR) analysis. Formalin-fixed, paraffinembedded normal human ovarian tissues (n = 10) and human GCT (n = 12) slides were
obtained from the Department of Pathology, Tianjin Medical University Cancer Hospital
and UNMC. The retrospective use of these human tissue slides was permitted by
protocols approved by the UNMC Institutional Review Board and Tianjin Medical
University Institutional Review Board.
The KGN GCT cells were derived from a patient with recurrent, metastasized GCT in
the pelvic region (91). These cells maintain many features of ovarian granulosa cells such
as expression of the FSH receptor and induction of aromatase (CYP19A1) and production
of estrogen in response to FSH. To date, to our knowledge, the KGN cell line is the only
appropriate cellular model for studying the growth and metastasis of the adult GCT (80,
92). In this study, we examined the role of YAP in the proliferation and migration of KGN
cells. The KGN cells used in these experiments were from passages 6 to 10. The cell line
was validated by STR polymorphism analysis performed by both the Riken BioSource
Center (Riken Cell Bank) and the Genetica DNA Laboratories (Burlington, NC, USA).
2.2.3. Immunohistochemistry analysis of YAP expression in ovarian tissues
The expression of YAP protein in paraffin-embedded human ovarian tissues was
detected using a previously described peroxidase-based immunohistochemistry protocol
(46). Immunosignals were visualized with a 3,3’-diaminobenzidine (DAB) kit (Invitrogen).
The sections were counterstained with Mayer’s hematoxylin. In case of negative controls,
the primary antibody was replaced by blocking buffer containing the same amount of IgG
from non-immune rabbit serum. The sections were scanned with an iSCAN Coreo Slide
Scaner (Ventana Medical Systems, Inc., Oro Valley, AZ, USA). The positivity (i.e., the
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number of positively stained cells relative to the total number of cells in the tissue section)
and the intensity of the positive immunosignals were quantified with Aperio ImageScope
software (Vista, CA, USA).
2.2.4. Localization of YAP protein in KGN cells
KGN cells were seeded onto glass coverslips and incubated in a growth medium
(DMEM/F12 supplemented with 5% FBS) for 36 h before fixation in ice-cold 4%
paraformaldehyde for 10 min. Staining was performed using methods described
previously (46). The fixed cells were incubated with YAP antibody (1:100) overnight at 4
°C in a humidified chamber. Antigens were visualized by applying Alexa-488-conjugated
donkey anti-rabbit secondary antibodies. Actin filaments were stained with rhodamineconjugated phalloidin and the nuclei were stained with 4’,6-diamidino-2-phenylindole
(DAPI). The images were captured and analyzed with an LSM 710 confocal microscope
(Thornwood, NY, USA). The exposure time of the camera was set for subtracting
background fluorescence that was present in the sections incubated with the nonimmune
IgG of the host species. YAP-specific fluorescence signals (immunosignal) were merged
with the nuclear and actin signals to determine the sub-cellular site of protein expression.
2.2.5. YAP mRNA expression
YAP mRNA expression in GCT cell lines was detected with RT-PCR as described
previously (46). Total RNA was isolated from primary cultures of normal human granulosa
cells, cultured GCT cell lines (KGN cells and COV434 cells), and epithelial ovarian cancer
(EOC) cells (SKOV-3, CAOV-3, and IGROV-1 cells) using the RNeasy mini kit (Qiagen,
Inc.) according to the manufacturer’s instructions. The first-strand cDNA was synthesized
from 1 μg total RNA using iScript cDNA synthesis kit (Bio-Rad). PCR products were loaded
onto an agarose gel and separated by electrophoresis. The images were captured by a
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UVP gel documentation system (UVP, Upland, CA, USA). The PCR products were
validated by sequence analysis.
2.2.6. Western blot analysis
Western blot was performed as described previously. Briefly, normal cell lines or
treated KGN cells were harvested on ice with ice-cold cell lysis buffer containing 10 mM
Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 1%
Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate and protease and phosphatase
inhibitor cocktails. Proteins (30 μg) were loaded onto a 10% SDS–PAGE gel, separated
by electrophoresis, and transferred onto nitrocellulose membranes. The membranes were
blocked with 5% BSA and probed with appropriate primary and HRP-conjugated
secondary antibodies. The immunosignal was detected with a Thermo Scientific
SuperSignal West Femto Chemiluminescent Substrate Kit. The images were captured and
analyzed with a UVP gel documentation system.
2.2.7. Establishment of wild-type and mutant YAP overexpressed cell lines
KGN cells were cultured to 40% confluence and then transfected with retrovirus-based
human YAP expression constructs. The characteristics and use of these vectors have
been reported previously (9). Two days following transfection, cells were selected with G418 (400 μg/ml) for 7 days. Three stable cell lines were established: i) the KGN–MXIV
control cell line was transfected with the control vector MXIV and expresses endogenous
YAP; ii) the KGN–YAP cell line overexpresses wild-type YAP protein; and iii) the KGN–
YAPS127A cell line expresses a constitutively activated YAP mutant. Mutation of YAP
protein (serine to alanine at residue 127) prevents YAP phosphorylation, leading to its
nuclear localization and constitutive activation.
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2.2.8. Cell proliferation assay
To determine the effect of YAP on GCT cell proliferation, KGN cells were plated in 60
mm cell culture dishes and incubated in a growth medium supplemented with 5% FBS
until 60% confluent. The cells were then transfected with siGLO (a cy5-labeled nontargeting siRNA as control) or YAP siRNA for 6 h using METAFECTENE (Biontex-USA,
San Diego, CA, USA) according to the manufacturer’s instructions. The cells were
harvested 72 h after siRNA transfection for determination of protein levels or cell numbers.
YAP protein expression was determined by western blot analysis and the cell numbers
were quantified with an Invitrogen Countess automated cell counter. The effect of YAP on
GCT cell proliferation was also determined in KGN cell lines that overexpressed the WT
or mutant YAP proteins. Each cell line was cultured in the growth medium containing 10%
FBS for up to 3 days. Cell number and cell size for each cell line were determined daily
with an Invitrogen Countess Automated cell counter.
2.2.9. Cell migration assay
A chemotaxis assay was used to determine the effect of YAP on KGN cell migration.
KGN cells (4 × 105) in 250 μl of serum-free DMEM were placed in a Transwell insert (8
μm pore size, Corning-Costar, Lowell, MA, USA). The inserts were then placed in the wells
of a 24-well-plate containing 750 μl of DMEM-FBS (5%) and incubated at 37 °C for 6 h.
After incubation, the cells on the top of the membrane were removed with a cotton swab.
The cells which had migrated to the underside of the membrane were fixed and stained
with 0.04% crystal violet in methanol for 30 min. The cells were then photographed (100
× magnification) and ten pictures per group were quantified under a microscope.
The wound-healing assay was also used to determine whether YAP regulates KGN
cell motility. KGN cells were cultured in six-well cell plates until confluent. Wounds were
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made by scratching the cell layer with a 100 μl pipette tip. After washing away the cell
debris, pictures were taken for each ‘wound’ with an Olympus inverted microscope
equipped with a DP71 digital camera (Olympus America, Inc., Center Valley, PA, USA).
The cells were incubated in serum-free medium for 20 h and then another picture was
taken for each ‘wound’.
2.2.10. Statistical analysis
All experiments were repeated at least three times unless otherwise noted. Data were
analyzed for significance by student T-test or one-way ANOVA with Tukey’s post-test. A
value of P < 0.05 was considered to be significant. Statistical analysis was conducted
using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA).
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2.3.

RESULTS

2.3.1. Expression of YAP protein in GCT
Adult GCT are commonly identified in women during the perimenopausal period (73).
The expression of YAP in the normal human ovary and GCT was detected by
immunohistochemistry. In control perimenopausal ovarian sections, the main cellular
component and the stroma, exhibited very little or no staining for YAP (Fig. 2-1 A, C, and
E). In control ovarian sections, few small follicles or luteinized structures were observed.
When follicles were present, YAP immunosignals were detected in granulosa cells and
were distributed in both nucleus and cytoplasm (too few follicles, data not shown). When
luteinized cells were present, YAP was predominantly localized to the cytoplasm (Fig. 21 C and E). Compared with the control ovarian tissues, YAP immunosignals were
significantly increased (P < 0.001) in the GCT tumor tissues and the protein was
predominantly located in the nucleus of tumor cells (Fig. 2-1 B, D, and F). Nontumor
stromal cells had low levels of YAP expression. Immunostaining controls revealed no nonspecific staining in GCT tissues (Fig. 2-1 G). The intensities of YAP immunostaining
signals were quantified with Aperio imagescope software (Aperio). The data showed that
both YAP signal intensity and YAP positivity (percentage of the YAP positive cells relative
to the total number of cells per section) in the ovarian GCT tissues were significantly higher
than the signals in the normal ovarian tissues (Fig. 2-1 H, P < 0.001).
2.3.2. Expression of YAP in ovarian GCT tumor cell lines
As mentioned earlier, the KGN cell is a suitable cellular model for the GCT research.
Fluorescent immunocytochemistry showed that YAP is expressed in KGN cells (Fig. 2-2
A). Most of the immunosignal was localized to the nucleus. Interestingly, the YAP
immunosignal was also localized to punctate regions in the periphery of the cells that co-
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localized with β-actin (Fig. 2-2 A). It is very possible that YAP may interact with the focal
adhesion proteins. Antibody controls using the same amount of IgG to replace the primary
YAP antibody were not stained (Fig. 2-2 A, lower panel).
RT-PCR and western blot analysis showed that YAP mRNA and YAP protein were
expressed in primary cultures of human granulosa cells, KGN and COV434 GCT cell lines
(Fig. 2-2 B and C). YAP RNA and YAP protein were also expressed in three ovarian
epithelial cancer cell lines (Fig. 2-2 B and C). IGROV-1 cells had lower expression of YAP
compared with SKOV-3 and CAOV-3 cells. It is well known that YAP protein activity is
highly regulated by phosphorylation. Western blot analysis revealed that phosphoYAP(S127) was present in each of the cell lines. Our results also showed that compared
with the KGN cells YAP was less phosphorylated in COV434 cells (Fig. 2-2 B and C), a
juvenile GCT cell line (73, 80).
2.3.3. Knockdown of YAP expression in KGN cells inhibits cell proliferation
To explore the role of YAP in GCT cell proliferation, we transiently transfected KGN
cells with two YAP siRNAs to knock down YAP expression. Cy5-labeled scrambled siRNA
(siGLO) was used as a control. Results showed that the transfection efficiency was very
high in the KGN cells, with more than 95% of cells being siGLO positive (Fig. 2-3 A).
Western blot analysis revealed that both YAP siRNA1 and siRNA 2 significantly (P <
0.001) reduced YAP protein in KGN cells (Fig. 2-3 B). The YAP knockdown KGN cells
were only 50–60% confluent compared with siGLO-treated cells, which were nearly 100%
confluent (Fig. 2-3 C). Quantification of cell numbers showed that compared with the
normal KGN cells or the KGN cells treated with siGLO, the cell numbers in the YAP
knockdown KGN cells was significantly reduced (~55%; P < 0.001; Fig. 2-3 D).
Knockdown of YAP not only suppressed cell proliferation but also affected cell
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morphology. As shown in Fig. 2-3 C, YAP-knockdown KGN cells were more spindleshaped compared with control KGN cells, indicating that YAP may regulate the actin
cytoskeleton of the KGN cells.
2.3.4. Overexpression of YAP promotes KGN cell proliferation and migration
To further explore the role of YAP in GCT cell proliferation, we established cell lines
which express the wildtype YAP protein (KGN-YAP) or the constitutively active YAP
protein (KGN-YAPS127A). The empty vector (MX) was also transfected into KGN cells and
served as a control cell line (KGN-MX). Results showed that compared with the control
cell line (KGN-MX), both KGN-YAP and the KGN-YAPS127A cells expressed more YAP
protein (Fig. 2-4 A). Morphologically, KGN-YAPS127A cells were smaller and much more
elongated compared with control cells (Fig. 2-4 B). Compared with the control group, cell
numbers almost tripled in KGN-YAPS127A cells and almost doubled in KGN-YAP cells within
24 h of plating (Fig. 2-4 C). After 3 days of culture, the number of KGN-YAPS127A cells
increased more than ten-fold, the number of KGN-YAP cells increased more than six-fold,
while the number of control cells (KGN-MX) increased only 2.5-fold (Fig. 2-4 C). We also
found that in comparison to the KGN-MX control cells, the diameter of KGN-YAP and
KGN-YAPS127A cells was reduced.
Transwell migration assays showed that cells in KGN-YAP group migrated faster than
cells in KGN-MX group, while cells in the KGN-YAPS127A group migrated faster than cells
in the KGN-YAP group (Fig. 2-5 A and B). This result was further confirmed by the woundhealing assay (Fig. 2-5 C). The morphology of the migrated cells further demonstrated
that the KGN-YAPS127A cells were smaller than the corresponding control KGN-MX cells
(Fig. 2-5 A).
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2.4.

DISCUSSION

2.4.1. Overview of previous studies and the present study on GCT
More than one and half centuries have passed since the first report of GCT in women
(93). The etiology and mechanisms underlying the progression and metastasis of GCT
are largely unknown. GCT are derived from granulosa cells, which are highly regulated by
reproductive hormones and growth factors in an endocrine, paracrine, and autocrine
manner (94, 95). Therefore, hormones, growth factors, and signaling pathways involved
in the regulation of normal ovarian granulosa cell functions may also affect the initiation
and/or progression of GCT. Indeed, several hormones and growth factors have been
implicated in the development of GCT. Inhibin-α has been suggested to be a critical GCT
tumor suppressor in rodents because the targeted deletion of the inhibin-α subunit in mice
resulted in ovarian granulosa-stromal tumors with very high penetrance (96). However,
human GCT are generally associated with high levels of circulating inhibins (97).
Therefore, the function of inhibin in the development of GCT in humans requires further
evaluation. Transgenic mice with constitutively activated WNT/b-catenin signaling in their
granulosa cells developed GCT (98), indicating that the WNT/b-catenin signaling pathway
maybe involved in the rodent GCT initiation and progression. However, it remains unclear
if the molecular mechanisms of tumorigenesis in this mouse model are related to those
involved in GCT development in women. A more recent whole transcriptome sequencing
study with human samples has demonstrated that a somatic mutation in FOXL2 (C402G;
Cys134TrP) was present in almost all morphologically identified adult-type GCT and
indicated that mutant FOXL2 is a potential driver in the pathogenesis of adult-type GCT
(79, 80). More recently, Rosario et al. found that patients with homozygous FOXL2
mutations had a significantly higher relapse rate (P < 0.04). However, they did not find a
significant correlation between FOXL2 mutation status or FOXL2 expression and any
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other clinical variables. The author’s indicated that due to the limitation of the sample size,
the prognostic significance of this gene mutation still needs to be confirmed (99).
Therefore, although nearly all adult GCT express the mutant FOXL2 gene, the
mechanisms underlying the progression, recurrence, and metastasis of ovarian GCT
remain unknown. In this study, our data clearly show that YAP, a central component of the
Hippo pathway, is highly expressed in human GCT tissues and that overexpression of
YAP protein significantly stimulates the proliferation and migration of the KGN GCT cell
line, demonstrating that the Hippo pathway may be involved in the progression of GCT.
2.4.2. YAP expression in GCT and ovarian epithelial cancer
YAP is the major downstream effector of the Hippo pathway. Activation of the Hippo
pathway suppresses YAP activity by phosphorylating YAP and subsequently retaining it
in the cytoplasm. In this study, we found that YAP immunostaining was significantly higher
in human GCT tumor tissues compared with normal ovarian tissues. Moreover, YAP was
mainly localized in the nucleus of tumor cells. In comparison, little YAP protein was found
in age-matched normal ovarian tissues. When luteinized cells were present in agematched normal ovarian tissues, YAP was mainly localized to the cytoplasm. Consistent
with our results, elevated YAP expression and nuclear localization have been observed in
multiple types of human cancers, including liver cancers, colon cancers, EOC, lung
cancers, and prostate cancers (9, 10, 67, 70). In hepatocellular carcinoma, YAP was
determined to be an independent prognostic marker for overall survival and disease-free
survival (100). In EOC, very recent data indicated that subcellular levels of YAP showed
an exceptionally strong association with poor patient survival (101). The authors
suggested that high levels of nuclear YAP, or low levels of cytoplasmic phosphorylated
YAP, were associated with poor survival in patients with EOC. Patients with both highnuclear YAP and low-phosphorylated YAP had about 50% lower 5-year survival, and this
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combination serves as an independent prognostic marker for survival (101). In another
study, levels of active nuclear YAP were reported to be expressed at high levels in around
14% of a cohort of 284 human ovarian cancer samples. Segregation by histotype showed
that the correlation between nuclear YAP and poor survival is predominantly associated
with clear cell tumors, independent of stage (102). As patient survival data are not
available for the samples used in this study, we cannot correlate YAP expression data
with survival of GCT patients. However, the high level of expression and nuclear location
of YAP protein in samples from GCT patients indicate that YAP may play important role in
regulation of GCT progression.
2.4.3. YAP promotes GCT progression
Control of ovarian cell proliferation is critical for the normal function of the ovary.
Uncontrolled granulosa cell proliferation and decreased cell death and/or differentiation
can lead to hyperplasia of the granulosa layer and the formation of GCT. Our results
indicate that dysregulation of the Hippo/YAP signaling pathway may contribute to
uncontrolled granulosa cell proliferation and development of GCT which expands the size
of the ovary. We used the KGN cell line as a model to determine the role of YAP in GCT
cell

proliferation.

Consistent

with

the

results

from

the

patient

samples,

immunohistochemical and molecular studies showed that KGN cells express YAP.
Knockdown of YAP protein in KGN cells with YAP-targeting siRNA significantly
suppressed cell proliferation without reducing cell viability, indicating that YAP is critical
for the proliferation of KGN cells. Furthermore, overexpression of YAP or its constitutively
active mutant (YAPS127A) in KGN cells stimulated KGN cell proliferation and migration,
indicating that the Hippo/YAP pathway may play a very important role in the regulation of
GCT cell growth and potentially GCT cell metastasis. Taken together, our results indicate
that YAP protein is required for the proliferation of KGN cells and the Hippo/YAP pathway
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might be one of the major pathways that are involved in the regulation of GCT progression.
To our knowledge, this is the first direct evidence showing the function of the Hippo/YAP
pathway in the progression of GCT.
The mechanism by which YAP regulates GCT cell proliferation is unclear. Granulosa
cells are highly regulated by gonadotropins, steroid hormones, and growth factors.
Abnormal activities in the pathways activated by any of these factors may induce
transformation of follicular granulosa cells and may promote GCT tumor growth,
recurrence, or metastasis. As a major effector of the Hippo pathway, YAP was reported to
interact with many important factors associated with GCT development. For example, YAP
has been reported to regulate the Wnt/b-catenin pathway in colorectal cancer. β-catenin
has been reported to be a potential initiator of GCT (98, 103). YAP was also reported to
interact with the TGFβ signaling pathway (104), which is a critical regulator of granulosa
cell proliferation (105). We have recently found that TGFα, via EGFR signaling pathways,
plays an important role in the proliferation of GCT cells (46). Interestingly, YAP was
reported to interact with EGFR to regulate cell proliferation (48, 106, 107). Future studies
on the interaction between the Hippo pathway and these critical regulators of ovarian
function may reveal novel mechanisms by which YAP promotes the initiation and/or
progression of GCT.
2.4.4. Conclusion
In conclusion, our data show that YAP is highly expressed in human GCT tissues and
is a critical regulator of proliferation and migration in the KGN human GCT cell line. We
propose that the Hippo-YAP signaling pathway may be involved in the regulation of GCT
growth and progression. YAP may be a potential novel biomarker for GCT diagnosis and
a promising target for the development of drugs for GCT therapy.
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Figure 2-1. YAP is expressed in human granulosa cell tumors (GCT).
Immunohistochemistry was used to examine the expression of YAP in normal ovarian
tissues (A, C, and E) and human GCT tissues (B, D, and F). YAP staining is indicated in
brown. The counter stain is hematoxylin, shown in blue. A) Whole-tissue section scan of
a representative normal ovary stained with YAP antibody; B) Scanned image of partial
ovarian GCT tissue stained with YAP. Amplified representative images of normal ovarian
tissues (C) and GCT tissues (D) stained with YAP antibody to show cell-type-specific YAP
expression. Representative high-resolution images were also presented to show the
subcellular localization of YAP in the normal ovarian tissues (E) and GCT tissues (F).
Tissue sections probed with the same amount of non-immunized rabbit IgG were used as
antibody control (G). (H) Quantitative results of DAB intensity were also presented to show
the difference of positivity (percentage of the number of DAB positive cells relative to
number of total cells in each tissue section) and relative intensity of YAP immunosignal
between normal human ovarian tissues (CTRL) and tumor tissues (GCT). Each bar
represents the mean ± S.E.M. *: P < 0.001 when compared with the control (CTRL)
groups. Scale bars = 2 mm in A and B; scale bars = 100 µm in C and D; scale bars = 50
µm in E and F; SC, stromal cells; CL, corpus luteum; TC, tumor cells.
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Figure 2-2. YAP is expressed in human ovarian GCT cell lines and epithelial ovarian
cancer cell lines.
A) Localization of YAP protein in KGN cells using fluorescent immunocytochemistry. (A1)
Total YAP (green); (A2) YAP protein (green) merged with actin filaments (red, stained with
Rhodamine-phalloidin). The nucleus was stained with DAPI (blue). (A3) KGN cells stained
with same amount of rabbit IgG (antibody control) and Rhodamine-phalloidin. Scale bars
= 25 um.
B) RT-PCR detection of YAP mRNA expression in cultured human granulosa cells
(human-GC), GCT cell lines (KGN and COV434) and ovarian cancer cell lines (IGROV-1,
SKOV-3, and CAOV-3). GAPDH was used as mRNA loading control.
C) Western blot detection of YAP protein expression in the same cell lines. β-tubulin was
used as protein loading control.
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Figure 2-3. YAP is required for KGN cell proliferation.
A) Fluorescence-labeled scramble siRNA (siGLO) indicates siRNA transfection efficiency
in KGN cells.
B) Western blot shows the downregulation of YAP protein after YAP siRNA treatments. βtubulin was used as a protein loading control. The lower panel shows the quantitative
results for the western blot. Bars represent means ± S.E.M. (n = 3).
C) Morphology of siGLO-transfected and YAP siRNA-transfected KGN cells. Scale bars =
100 µm.
D) KGN cells were transfected with YAP siRNAs for 6 h and then cultured for another 72
h. Cell numbers in each group were determined with an INVITROGEN Countess
automatic cell counter. Each bar represents the mean ± S.E.M. (n = 5). Bars with the
different letter are significantly (P < 0.05) different from each other.
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Figure 2-4. Overexpression of YAP stimulates KGN cell proliferation.
A) Empty plasmid-transfected KGN cells (KGN-MX), wildtype YAP overexpression cells
(KGN-YAP), and mutant YAP-transfected KGN cells (KGN-YAPS127A) were plated in sixwell plates and the levels of YAP and phosphorylated YAP in these established stable cell
lines were examined by western blot. β-tubulin was used as a protein loading control.
B) Upper panel: morphological difference between mutant YAP-transfected KGN cells
(KGN-YAPS127A) and Empty plasmid-transfected KGN cells (KGN-MX). Scale bars = 100
µm. Lower panel: actin filaments stained with Rhodamine-phalloidin to demonstrate the
morphological change between the two established cell lines. Nuclei were stained with
DAPI. Scale bars = 25 µm.
C) Effect of YAP overexpression on KGN cell proliferation. Control KGN cells (KGN-MX),
KGN-YAP cells, and KGN-YAPS127A cells were incubated for 24, 48, and 72 h, respectively,
and the cell number was counted with an INVITROGEN Countess automatic cell counter.
Each bar represents the mean ± S.E.M., n = 5. Bars with the same letter are not
significantly (P < 0.05) different from each other.
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Figure 2-5. YAP regulation of KGN cell migration.
A) KGN-MX cells, KGN-YAP cells, and KGN-YAPS127A cells were loaded to a Transwell
migration assay chamber and the migration assay was performed as described in the
materials and methods section. Top panel, representative image of the migrated KGN-MX
cells. Lower panel, representative image of the migrated KGN-YAPS127A cells. Scale bars
= 100 µm.
B) Migrated cells in each group were counted and the fold change (relative to the KGNMX control group) of the migrated cells was determined. Each bar represents the mean ±
S.E.M. (n = 12). Bars with the same letter are not significantly (P < 0.05) different from
each other.
C) Evaluation of the cell migration ability with the wound-healing assay. Representative
images from triplicate experiments were presented. Scale bars = 100 µm.
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CHAPTER 3: YAP INDUCES HIGH-GRADE OVARIAN CANCER WITH
MESENCHYMAL FEATURE FROM POORLY DIFFERENTIATED
GRANULOSA CELLS‡

‡

The material presented in this chapter was submitted as a manuscript: Lv et al. 2017.
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ABSTRACT
Understanding the cell-of-origin of high-grade serous ovarian cancer (HGSOC) is the
prerequisite for efficient prevention and early diagnosis of this most lethal gynecological
cancer. However, the cell-of-origin of HGSOC is under debate. Recently, a novel
mesenchymal subtype of HGSOC with poor prognosis was identified by both The Cancer
Genome Atlas (TCGA) and Australian Ovarian Cancer Study (AOCS) studies. But the cellof-origin of this subtype of HGSOC has not been defined. Our previous studies
demonstrated the critical role of Yes-associated protein 1 (YAP) in the development of
ovarian cancer. In the present study, we show that YAP can induce high-grade ovarian
cancer from poorly differentiated granulosa cells. Employing xenograft mouse models,
overactive YAP elicited malignant ovarian cancer development in the peritoneal cavity of
host mice from granulosa cells. Histologically and genetically, tumors developed in our
mouse models resembled women’s HGSOC. Intriguingly, these tumors overexpressed Ncadherin and vimentin but had low expression of CA125 and E-cadherin, reminiscent of
the recently identified mesenchymal subtype of HGSOC. Our studies suggest the
granulosa cells as a previously unprecedented cell-of-origin for the mesenchymal type of
HGSOC.
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3.1.

INTRODUCTION

3.1.1. High-grade serous ovarian cancer
Ovarian cancer is the most lethal gynecological cancer, ranking the fifth leading
cancer-related death in women. In worldwide, 238,700 women are estimated to be
diagnosed with ovarian cancer annually, with 151,900 ovarian cancer associated deaths
(108). Ovarian cancers are collective tumors with distinguished features and origins. Highgrade serous ovarian cancer (HGSOC), which accounts for 70-80% ovarian cancer death,
is the most common and lethal ovarian cancer (109, 110). HGSOC patients almost always
are diagnosed at advanced clinical stages. The aggressive nature of this disease makes
the patients have a very poor overall survival. The obstacles for the early diagnosis and
better treatments for HGSOC are the controversial cell of origin and the unclear molecular
etiology of this disease.
3.1.2. Origin of HGSOC
More often than not by the time the disease has been detected the cancer cells are
already widespread to other tissues or organs, making it challenging to assess origin of
HGSOC (111). Supported by studies from epidemiology, pathology, genetics, and animal
model, fallopian tube secretory epithelial cells (FTSECs) are recognized as the cell origin
of a substantial proportion of HGSOC, although it is called ovarian cancer (110).
Increasing evidence indicated that HGSOCs originate as serous tubal intraepithelial
carcinomas (STICs) located on distal oviductal fimbriae, however, the development of
some HGSOCs seem to come from somewhere other than the fallopian tube since only
about 60% of HGSOCs have been found accompanied by STICs (112, 113). An
alternative origin is the lining epithelial of cortical inclusion cysts in the ovary, which are
considered to be derived from the invaginations of ovarian surface epithelium (OSE) (114,
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115). Mesothelial OSE cells are believe to retain stem-cell characteristics including
pluripotency and thus can undergo serous metaplasia to further develop HGSOC (116).
3.1.3. Novel mesenchymal subtype of HGSOC
Next generation sequencing technology made it possible to classify HGSOC based on
their genomic signature. By mining The Cancer Genome Atlas (TCGA) database and
analyzing the gene expression profile of ovarian high-grade serous cancer patients, the
TCGA group described 4 subtypes of ovarian HGSOC, termed “differentiated”,
“immunoreactive”, “proliferative”, and “mesenchymal” subtypes (117). Consistently, an
earlier study by the Australian Ovarian Cancer Study (AOCS) Group identified subtypes
of HGSOC consistent with this classification (118). Importantly, both studies identified the
mesenchymal type of HGSOC with poor prognosis (117, 118). This subtype of HGSOC
has a mesenchymal or dedifferentiated phenotype, with overexpression of N-cadherin and
vimentin but low expression of conventional ovarian cancer marker CA125 and Ecadherin. The cell-of-origin of the newly identified mesenchymal type of HGSOC is yet to
be identified.
3.1.4. Ovarian granulosa cells
Ovarian granulosa cells contribute to most of the somatic component of ovarian follicle.
The proliferation and differentiation of granulosa cells are critical regulated to support
follicle growth and oocyte maturation. The granulosa cell tumor (GCT) is thought to
originate from differentiated granulosa cells of the late preovulatory follicle, maintaining
many features of these cells including hormone production and response to gonadotropins
(73). Expressing stem/tumor cell markers like MYC, KLF4, and TERT, poorly differentiated
granulosa cells at early-stage follicles possess properties of stem/ tumor cells, including
multipotential, indefinite self-renewal, loss of cellular contact inhibition, and anchorage-
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free growth (35, 119-121). With mesenchymal features, granulosa cells have been
demonstrated to transdifferentiate to neuron-like cells, osteoblasts, and chondrogenic
lineages (120, 122).
3.1.5. Hippo-YAP signaling
First discovered in Drosophila, the Hippo-YAP pathway is highly conserved among
species. The Hippo-YAP pathway has attracted growing interest in the research field due
to its fundamental role in organ size control, stem cell function, and tumorigenesis (4, 7,
123). The transcriptional co-activator Yes-associated protein 1 (YAP) is the pivotal effector
of the Hippo-YAP pathway. The Hippo pathway can phosphorylate YAP and subsequently
exclude it from the nucleus to inhibit transcriptional activity of this oncoprotein (4, 5).
Extensive studies have shown that YAP is overexpressed in a broad range of human
cancer and promotes tumorigenesis (4, 64). YAP is also highly expressed in
stem/progenitor cells in intestine, skin, liver, nerve, lung, heart, and muscle tissues, which
is critical for stem/progenitor cell function (124, 125). Our previous reports demonstrated
that YAP is overexpressed in ovarian cancers including HGSOC and YAP plays a
significant role in the initiation and progression of ovarian cancers by interaction with
ERBB and FGFR signaling pathways (23, 50, 51).
3.1.6. Present study
In the present study, unexpectedly, we found that overactive YAP elicited development
of high-grade ovarian cancer with characteristics of mesenchymal type from poorly
differentiated ovarian granulosa cells in xenograft mouse models, reminiscent of the
mesenchymal subtype of HGSOC identified recently in women patients (117, 118). Our
research unveiled a novel potential cell-of-origin of the mesenchymal type of HGSOC.
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3.2.

MATERIALS AND METHODS

3.2.1. Cell culture
HGrC1 cell lines was obtained from the Riken Biosource Center (Riken Cell Bank,
Ibaraki, Japan). Cell lines were validated using short tandem repeat (STR) polymorphism
analysis performed by Genetica DNA Laboratories (Burlinton, NC, USA). Cells were
cultured in DMEM/F12 with supplement of Ultroser G serum substitute and antibiotics at
37 ◦C, 5% CO2, and 95% air condition.
3.2.2. Retrovirus system for overexpression
HGrC1 cells were overexpressed with YAP or YAPS127A vectors (given by Dr. Jixin
Dong at University of Nebraska Medical Center) and p53R175H vector (a gift from Dr. Jeffrey
N Myers at MD Anderson Cancer Center). Empty vector transfected HGrC1 cells were
used as control. Recombinant retrovirus was generated as following: after co-transfecting
HEK293GP cells with equal amounts of VSVG packaging vector and one of the following
retroviral expression vectors: pMX-neo-YAP, pMX-neo-YAPS127A, pBABE-puro-p53R175H
using Lipofactamine@ 3000 Transfection Reagent (Grand Island, NY), medium was
replaced overnight. Viral supernatants were harvested at 48 h and 72 h post transfection
by passing through a 0.45-μm filter. Then these viruses can be stored at -80 ◦C or directly
used to infect target cells with 8 μg/mL polybrene overnight, followed by fresh medium
change. After 72 h post infection, appropriate selective antibiotics were added to the
culture medium to select positive cells (HGrC1-YAP, HGrC1-YAPS127A, HGrC1-p53R175H,
HGrC1-YAPS127Ap53R175H). The selection period lasted more than 1 week until no cells
survival in the uninfected wells.
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3.2.3. CRISPR Cas9 system to knockout BRCA1
The lentivirus containing CRISPR Cas9 system vectors to knockout BRCA1 gene were
purchased from Applied Biological Materials Inc. (Richmond, BC, CANADA). Target cells
were infected with lentivirus overnight and selected with puromycin after 72 h infection
similarly as retrovirus infection procedure.
3.2.4. Cell proliferation analyses
Cell numbers were monitored with an Invitrogen Countess automated cell counter as
described in chapter 1.
3.2.5. Western blot
Cell lysis was harvested and protein was analyzed by western blot as above
description in chapter 1.
3.2.6. Three-dimensional hanging drop cell culture
A three-dimensional (3D) culture system, GravityPLUS™ 3D Cell Culture plate
(InSphero, Schlieren, Switzerland), was employed to mimic cell growth in vivo as
described in chapter 1.
3.2.7. Colony formation assays
Cell transformation in vitro was determined using a Cytoselect 96-Well Cell
Transformation assay kit (Cell Biolabs, Inc., San Diego, CA) according to the
manufacturer’s instructions. Briefly, equal numbers of cells in different group as indication
were plated in 0.6% soft agar condition and cultured with treatments or not for 10 days.
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MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used to stain
colonies, which were then imaged and counted.
3.2.8. Immunohistochemistry and immunocytochemistry
Immunohistochemistry and immunocytochemistry analyses were performed using
indicated antibodies as description in chapter 1.
3.2.9. Hematoxylin and eosin stain for histology analyses
Mouse xenografts were harvested and fixed with formalin. After paraffin-embedding
and section, Hematoxylin and eosin (H & E) stain was performed for xenograft tissue
slides. Histology analyses was conducted by the pathologist Dr. Yun-An Tseng at
University of Nebraska Medical Center.
3.2.10. Alcian blue pH 2.5-periodic acid–Schiff stain
To determine the production of sulfated and carboxylated acid mucopolysaccharides
and sialomucins in the tumor tissues, Alcian blue pH 2.5-periodic acid–Schiff (PAS) stain
was performed. The colorectal epithelium tissues were used as a positive control for PAS
stain. The sections were counter-stained with hematoxylin.
3.2.11. Xenograft mouse model
Cells (2 × 107) were trypsinized and collected by centrifugation. Cells in the pellet were
suspended in 250 μl of DMEM/F12 with 250 μl of Matrigel (BD Biosciences Inc.) on ice.
This mixture was injected subcutaneously or intraperitoneally into 5-week-old female Nude
(Nu/J, Envigo) or NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory #
005557) mice. Mice were closely monitored after cell implantation. For intraperitoneal
injection, after mice became very sick with distention in abdomen and weight loss, mice
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were euthanized and solid tumors were collected for preparation of protein, RNA and
paraffin tissue sections. The ascites was harvested and ascites cells were separated by
centrifuge for culture. All animal experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) at University of Nebraska Medical Center.
3.2.12. Array Comparative Genomic Hybridization (aCGH).
Genomic DNA extracted from xenografts, cultured ascites cells, and control HGrC1
cells was hybridized with normal reference DNA to the Cancer Microarray (Agilent 180K
CGH+SNP Array, CCMC design, GRCh37) to perform aCGH profiling. This array targets
genes associated with cancer at 5-10 kb copy number resolution and provides 25 kb whole
genome copy number coverage for precise breakpoint delineation. Copy number changes
> 500 kb in size will be reported as well as copy-neutral loss of heterozygosity (LOH).
3.2.13. Statistical analysis
All experiments were performed at least three times unless otherwise noted. The data
are presented as representative experiments or as the means ± SEM of the averages from
multiple experiments. Statistical analysis was conducted using GraphPad Prism software
(GraphPad Software, Inc. La Jolla, CA). Statistical comparisons between two groups were
analyzed for significance by two-tailed Student’s t-test. Multiple group comparisons were
assessed by one-way analysis of variance with Tukey’s post-Hoc test. P ≤ 0.05 was
considered statistically significant.
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3.3.

RESULTS

3.3.1. Overactive YAP induces malignant tumors from poorly differentiated human
granulosa cells
To explore the role of YAP in the malignant transformation of early-stage granulosa
cells, we used HGrC1 as cellular model, which is an immortalized human granulosa cell
line derived from poorly differentiated granulosa cells in the early stage of ovarian follicle
development (126). As described above, we established HGrC1-MX (control), HGrC1YAP (expressing wild-type of YAP), and HGrC1-YAPS127A (expressing constitutively active
YAP) three cell lines (Fig. 3-1 A). Overexpression of both wild-type and constitutively
active YAP dramatically accelerated granulosa cell growth compared with control, while
HGrC1-YAPS127A grew most rapidly (Fig. 3-1 B). In the 3D culture system, overexpression
of wild type or constitutively active YAP significantly increased the volume of spheroids,
with HGrC1-YAPS127A group forming the largest spheroids (Fig. 3-1 C). These results
demonstrate that YAP overactivation promotes granulosa cell overgrowth.
To examine the role of YAP in the malignant transformation of undifferentiated
granulosa cells in vitro, we performed soft agar assays. As immortalized non-transformed
HGrC1 cells, control HGrC1-MX cells formed few or no colonies in the soft agar culture
(Fig. 3-1 D). In contrast, HGrC1-YAP and HGrC1-YAPS127A cells formed many colonies,
and HGrC1-YAPS127A cells formed more colonies than HGrC1-YAP (Fig. 3-1 D). These
results suggested that YAP induces malignant transformation of poorly differentiated
HGrC1 granulosa cells.
Consistent with in vitro experiments, HGrC1-YAP and HGrC1-YAPS127A cells, but not
HGrC1-MX cells, formed tumors after subcutaneous injection of these cells into the nude
mice (Fig. 3-1 E). Tumors derived from HGrC1-YAPS127A cells grew significantly faster than
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those derived from HGrC1-YAP cells (Fig. 3-1 F & G). Surprisingly, histological analysis
showed that tumors derived from HGrC1-YAP and HGrC1-YAPS127A cells were not like
typical granulosa cell tumors. H & E staining showed that tumor cells in xenograft tissues
have pleomorphic nuclei, but not typical coffee bean-like nuclei (Fig. 3-1 H). These tumor
tissues have no typical histological structures of GCT such as Call-Exner bodies,
trabecular pattern, or macrofollicular structures (Fig. 3-1 H). These tumor cells were very
proliferative, indicated by high mitotic index in the H & E staining, and the high expression
of Ki-67 (Fig. 3-1 H & I). Moreover, IHC studies showed that these tumor cells have
undetectable expression of aromatase which is the biomarker of GCT (Fig. 3-1 I). YAP
staining confirmed the overexpression of YAP in tumor cells (Fig. 3-1 I). In addition, tumor
cells were malignant, with invasion into adjacent adipose and muscle tissues. Together,
these tumors are more likely poorly differentiated ovarian cancers, rather than granulosa
cells tumors.
3.3.2. YAP overactivation induces malignant ovarian cancers like high-grade
serous ovarian cancer from granulosa cells
Because TP53 mutations are identified in most of ovarian cancer patients, mutant
TP53 is considered as a driver mutation in the pathogenesis of ovarian cancer (127, 128).
To mimic the genetic alternations of ovarian cancer, we introduced the mutant p53R175H
into HGrC1 cells. In vitro studies showed that mutant p53 (HGrC1-p53R175H) alone cannot
transform HGrC1 cells, as indicated by the colony formation assays (Fig. 3-2 A).
Introduction of p53R175H into HGrC1-YAPS127A cells (HGrC1-YAPS127Ap53R175H) slightly
increased colony formation (Fig. 3-2 A). As an ovarian cancer susceptibility gene, BRCA1
gene mutations predispose women to ovarian cancer and more than 20% of ovarian
cancer patients have been found to have loss-of-function BRCA1, including inherited
mutations, somatic mutations, and promoter methylation (128). With the introduction of
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BRCA1 gene deletion by the CRISPR Cas9 system, HGrC1-YAPS127Ap53R175HBRCA1-/cells formed more colonies compared with HGrC1-YAPS127Ap53R175H group, suggesting the
significant role of BRCA1 in ovarian cancer development.
Most patients diagnosed with ovarian cancer present at later stages, at which ovarian
cancer cells have spread in the peritoneal cavity. To mimic the environment of ovarian
cancer development, we intraperitoneally injected HGrC1-CTL, HGrC1-p53R175H, HGrC1YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells into NSG
mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory # 005557) to monitor
cancer development. Consistent with in vitro studies, all mice implanted with HGrC1 cells
with

overactive

YAP

(HGrC1-YAPS127A,

HGrC1-YAPS127Ap53R175H,

and

HGrC1-

YAPS127Ap53R175HBRCA1-/- 3 groups) developed malignant cancers, accompanied by
abdomen distension and weight loss (Fig. 3-2 B). Late stage cancers were associated with
large amount of ascitic fluid in the peritoneal cavity (Fig. 3-2 B). After open the abdomen,
we found that tumors were widespread in the peritoneal cavity and metastasized to
multiple organs/tissues including diaphragm, mesentery, peritoneum, pancreas, and liver
(Fig. 3-2 B), which is reminiscent of the typical presentation of malignant human ovarian
cancer. Histological analyses further support the metastasis of tumors to multiple
organs/tissues in the peritoneal cavity and also metastasis to outside muscle tissues,
indicating the malignance of these tumors (Fig. 3-2 C). Moreover, the Kaplan-Meier
survival analysis of these host mice showed that all tumor-burden mice died in 6 months
(Fig. 3-2 D). HGrC1-YAPS127Ap53R175HBRCA1-/- hosted mice start to die at 2 months after
injection, while HGrC1-YAPS127A and HGrC1-YAPS127Ap53R175H injected mice had similar
survival time and started to die after injection for 3 months (Fig. 3-2 D). The median
survival times are 99 days for HGrC1-YAPS127Ap53R175HBRCA1-/- mice, 130 days for
HGrC1-YAPS127Ap53R175H mice, and 127.5 days for HGrC1-YAPS127A mice, respectively
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(Fig. 3-2 D). Log-rank test suggested that mutation of TP53 (p53R175H) had no significant
effect on the mouse survival rate. However, deficiency of BRCA1 gene in the
YAPS127Ap53R175H mice significantly hastened the onset of death and reduced survival time
(P < 0.001) (Fig. 3-2 C), indicating BRCA1 loss promotes ovarian cancer development.
Hematoxylin and eosin staining showed the histology of tumors resembled HGSOC
(129, 130). Tumor cells are distinct pleomorphism and marked nuclear atypia, with
prominent nucleoli (Fig. 3-2 C). These tumor tissues have a very high mitotic index,
including many abnormal mitotic figures (Fig. 3-2 C). Tumor cells isolated from the ascitic
fluid were very proliferative in culture and nuclear atypia is a common feature of these
cells. Consistently, immunohistochemistry analysis showed that proliferation marker Ki67
is highly expressed in tumor tissues (Fig. 3-3 A). Moreover, WT1, PAX8, MYC, and keratin
7 proteins were detected in the tumor cells with immunohistochemistry (Fig. 3-3 A), which
are characteristics of ovarian HGSOC (129, 131). YAP and p53 expression in the tumor
cells were confirmed (Fig. 3-3 A & D). In addition, tumor tissues were stained negative for
aromatase and inhibin, which are two markers for granulosa cell tumors (Fig. 3-3 B).
PAX2, a marker for low grade serous carcinoma, and mucinous ovarian cancer marker
cytokeratin 20 were also negative in the immunohistochemistry examination (Fig. 3-3 B)
(132, 133). We further determined that tumor tissues were negative for Alcian blue (pH
2.5)-periodic acid–Schiff (PAS) staining, confirming that these tumors are not mucinous
ovarian cancers (Fig. 3-3 C) (134). These findings support pathological diagnoses that
these tumors are like HGSOC, but not other ovarian tumors.
Western blot results further confirmed the expression of WT1, PAX8, MYC and keratin
7 in tumor cells (Fig. 3-4). Interestingly, we found overactive YAP induced increasing
protein expression of WT1, PAX8, and MYC in poorly differentiated granulosa cell HGrC1
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(Fig. 3-4). The expression of YAP, p53, and BRCA1 were also confirmed by Western blots
(Fig. 3-4).
One of the most important features of HGSOC is genome instability (128, 135), we
performed array comparative genomic hybridization (aCGH) to examine whether tumors
developed in our mouse models resemble human HGSOC at the genomic level. YAP
overactivation induced considerable genome instability in tumor cells (Fig. 3-5). Combined
with YAP overactivation, p53 mutation, and BRCA1 deletion, tumors cells presented
multiple regions of DNA gain and loss, indicating severe genome instability, which is the
genomic feature of human HGSOC (Fig. 3-5).
3.3.3. YAP induces high-grade ovarian cancers with mesenchymal features from
granulosa cells
Interestingly, these tumor cells retain some mesenchymal features of ovarian
granulosa cells. We detected an elevated level of mesenchymal markers like N-Cadherin
and vimentin but a low level of CA125 and E-Cadherin expression in these tumors with
immunohistochemistry and western blot analyses (Fig. 3-3 A & B and Fig. 3-4). Recently,
TCGA and AOCS studies identified a novel molecular subtype of high-grade serous
carcinoma in patients which reflect a mesenchymal cell type, with overexpression of
mesenchymal markers including N-cadherin and vimentin but with low CA125 and Ecadherin expression (117, 118). This mesenchymal type HGSOC predicts a reduced
overall survival (117, 118). With similar aggressive mesenchymal features, the tumors
derived from our mouse models resemble this novel mesenchymal subtype of HGSOC in
human.
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3.4.

DISCUSSION

3.4.1. YAP induces high-grade ovarian cancers from poorly differentiated
granulosa cells
In the present study, we show that overactive YAP induced HGSOC with
mesenchymal features from poorly differentiated granulosa cells. Tumor cells in
subcutaneous xenograft tissues have pleomorphic nuclei in high-grade ovarian cancer
(129, 136), but not coffee bean-like nuclei in GCT (137). These tumors also do not have
typical histological characteristics of GCT like Call-Exner bodies, trabecular pattern, or
macrofollicular structures (137). Moreover, these tumor tissues have very high mitotic
index, which is indicated by the presence of many cells with mitotic figures and the high
expression of Ki-67. Furthermore, IHC studies showed that these tumor cells have
undetectable aromatase and inhibin, which are biomarkers of GCT. Based on the histology
and molecular features, these tumors are more like poorly differentiated ovarian
carcinoma but not like GCT.
After intraperitoneal implantation of YAPS127A overexpressing granulosa cells (HGrC1YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells), large
amounts of ascites in the peritoneal cavity were induced in the later stage of tumor
progression. These tumor cells were very invasive and metastasized to the omentum,
mesentery, visceral fat tissue, diaphragm membrane, liver, pancreas, and muscle tissues.
Histological studies showed that the nuclei of these tumor cells are highly pleomorphic
and larger with coarsely clumped chromatin. Moreover, these tumor tissues have very
high mitotic index, including many abnormal mitotic figures. Furthermore, cultured tumor
cells derived from the ascitic fluid were very proliferative and the nuclear atypia was very
common. In addition, the known biomarkers for HGSOC, such as high Ki-67, PAX8, WT1,
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Keratin 7 are expressed in the cancer cells derived from all three YAPS127A expressing
cells (129, 132, 138). The morphological features and negative expression of PAX-2 in
these tumor cells suggest that these tumors are not low-grade serous carcinomas (129).
The negative keratin 20 and PAS staining suggests that these tumors are not mucinous
ovarian cancers (132). The molecular features of these tumors indicated that these tumors
are high-grade ovarian carcinoma with serous features.
3.4.2. YAP elicits mesenchymal subtype of HGSOC from poorly differentiated
granulosa cells
Both the TCGA and AOCS studies revealed multiple subtypes of human HGSOC,
including “differentiated”, “immunoreactive”, “proliferative”, and “mesenchymal” 4
subtypes (117, 118). Of importance herein, both groups identified a mesenchymal type of
HGSOC with poor prognosis (117, 118). Due to its mesenchymal molecular features, the
cell-of-origin for the newly identified mesenchymal type of HGSOC remains unknown.
However, it is known that this type of HGSOC has very high level of mesenchymal markers
including N-cadherin and vimentin, but it has very low expression of epithelial proteins like
E-cadherin and CA125 (MUC16) (117, 118). In the present study, we found that
overactivation of YAP in the poorly differentiated ovarian granulosa cells induced HGSOClike tumors. Importantly, these tumors express high levels of N-cadherin and vimentin but
have low expression of E-cadherin and CA125. Granulosa cells are mesenchymal type of
ovarian cells, which can be induced to differentiate into osteoblast, muscle cells and
neurons (120, 122). The tumor cells derived from poorly differentiated granulosa cells in
our mouse models kept their mesenchymal cell markers such as N-cadherin and vimentin.
Based on these novels findings, we speculate that poorly differentiated granulosa cell
could be a potential cell-of-origin of the lethal mesenchymal type of HGSOC.
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The mechanism by which YAP induces the mesenchymal type of HGSOC from
granulosa cells is unclear. Granulosa cells are very special cells in human body. Previous
studies have shown that a subpopulation of granulosa cells in early-stage follicles (poorly
differentiated granulosa cells) possess properties of stem or tumor cells, including loss of
cellular contact inhibition and anchorage-free growth (119, 121, 139, 140).

Isolated

granulosa cells express stem cell markers with high telomerase activity, and can
differentiate into other cell types (120, 141, 142). This evidence suggests that poorly
differentiated granulosa cells are mesenchymal cells with high plasticity. As an
oncoprotein, YAP has also been implicated in stem cell function of embryonic stem cells,
adult stem cells, and cancer stem cells (125). Importantly, YAP has been shown to be
overexpressed in cancer stem cells and high-grade carcinomas (68, 143, 144). Very
recent studies show that YAP was able to induce terminally differentiated luminal breast
epithelial cells, neurons, and the pancreatic acinar cells into tissue specific pluripotent cells
(145). Therefore, it is possible that disruption of the Hippo pathway in granulosa cells leads
to overactivation of YAP, which may induce dedifferentiation of granulosa cells and
uncontrolled proliferation. Further loss function of p53 and BRCA1 can induce malignant
transformation, eliciting poorly differentiated ovarian cancers. The observation that
mesenchymal type of HGSOC is characterized with poorly differentiated phenotype
supports our idea (118). The detailed mechanism underlying YAP regulation of granulosa
cell reprogramming and transformation warrants further investigations. Currently, we are
also using several mouse strains to study the tumorigenesis of granulosa cells.
3.4.3. The genomic instability of HGSOC
Cell reprogramming factors have potential to induce DNA damage (146). DNA damage
response pathways might be a potential link between somatic cell dedifferentiation and
tumorigenesis. p53 plays critical role in the cellular DNA damage response process to
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protect cells from potential inherited chromosomal aberrations during the process of
dedifferentiation. Abrogation of p53 leads to persistent DNA damage and chromosomal
aberrations during cell reprogramming (146, 147). Importantly, recent studies showed that
mutated p53 could promote tumor progression via gain-of-function, further supporting the
importance of p53 in the development of HGSOC (148-150). Similarly, BRCA1/2 are also
critical for maintaining genome stability (151, 152). Unfortunately, TP53 is mutated in the
majority of patients with HGSOC (128). Abnormal inactivation of BRCA1/2 genes is
considered to contribute to the development of more than half of HGSOC (110). Genome
instability is one of the most important genetic features of HGSOC (128, 135). In the
present study, we found that YAP overactivation was able to induce malignant ovarian
tumors from poorly differentiated granulosa cells with genome instability, which is
supported by recently studies showing genome instability induced by YAP (153, 154).
Combined YAP overactivation with alternations of TP53 and BRCA1 genes, two notorious
susceptibility genes in HGSOC, tumor progression was significantly promoted. More
importantly, tumor cells shown severe genome instability, mimicking the genetic feature
of human HGSOC. Therefore, with the combination of overactive YAP oncoprotein and
inactivation of tumor suppressors p53 and/or BRCA1, poorly differentiated granulosa cells
can be vulnerable for malignant transformation, leading to the development of
mesenchymal type of HGSOC.
3.4.4. Clinical significance
Our findings have significant clinical relevance. Tumor heterogeneity in histology and
genome has been blamed, in part, for the poor prognosis of the HGSOC. Understanding
on the cell-of-origin of different subtype of HGSOC and the molecular events underlying
the initiation and progression of HGSOC should provide clues for the effective prevention,
early diagnosis, and personalized treatment of HGSOC. In the present study, we showed
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that disruption of the Hippo-YAP pathway may result in malignant transformation of
ovarian poorly differentiated granulosa cells, leading to the development of HGSOC with
mesenchymal features. Targeting the Hippo-YAP pathway may represent a novel strategy
for the improved treatment of HGSOC.
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Figure 3-1. YAP induces non-granulosa cell tumors from poorly differentiated
granulosa cells.
A). Western blot showing overexpression of wild type YAP and constitutively active
S127A

YAP

protein in HGrC1 cells. β-Actin as control.

B) Overexpression of YAP promotes HGrC1 cell proliferation; each point on the growth
curves represents the mean ± SEM (n ≥ 4); when compared with control at 10 d, **: P <
0.01, ***: P < 0.001.
C) Representative pictures and quantitative data showing the size of spheroids formed by
HGrC1-MX, HGrC1-YAP, and HGrC1-YAPS127A cells in the 3D culture system after
loading for 5 d; scale bar: 200 μm; each bar represents the mean ± SEM (n ≥ 4); bars with
different letters are significantly different from each other (P < 0.05).
D) Representative images and quantitative data showing colony formation by HGrC1-MX,
HGrC1-YAP, and HGrC1-YAPS127A cells; scale bar: 500 μm; each bar represents the
mean ± SEM (n ≥ 4); bars with different letters are significantly different from each other
(P < 0.05).
E) Representative pictures show tumor formation by HGrC1-YAP and HGrC1-YAPS127A
but not HGrC1-MX cells using xenograft mouse models.
F) Tumor growth indicated by increasing volume of tumors; each point on the growth
curves represents the mean ± SEM (n = 10); when compared with control at the end point,
***: P < 0.001.
G) Bar graph showing tumor weight; each bar represents the mean ± SEM (n = 10); bars
with different letters are significantly different from each other (P < 0.05).
H) Representative picture showing hematoxylin and Eosin stain (H & E) of tumor tissues;
scale bar: 50 μm.
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I) Representative images showing the expression of Ki67, aromatase, and YAP in tumor
cells by immunohistochemistry; scale bar: 50 μm.
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Figure 3-2. YAP induces malignant ovarian cancers from poorly differentiated
granulosa cells.
A) Representative images showing colonies formed by HGrC1-CTL, HGrC1-p53R175H,
HGrC1-YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells;
scale bar: 500 μm; right graph showing quantitative data of colony numbers; each bar
represents the mean ± SEM (n ≥ 6); ns: no significance, **: P <0.01, ***: P < 0.001.
B) Representative images show that ascites presents and malignant ovarian cancer
spreads in the mouse abdomen, including peritoneum, mesentery, diaphragm, pancreas,
and liver, in the host mice intraperitoneally injected with HGrC1-YAPS127A, HGrC1YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells; the same color of arrows
and organ/tissue names are matched.
C) Representative images showing the histology of the malignant ovarian cancers
metastasized to multiple organs/tissues; scale bar: 50 μm.
D) Survival data of host mice injected with HGrC1-CTL, HGrC1-p53R175H, HGrC1-YAPS127A,
HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells.
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Figure 3-3. YAP elicits HGSOC-like tumors from poorly differentiated granulosa
cells.
A) Representative images showing expression of Ki-67, WT-1, PAX8, Myc, Keratin 7
(KRT7), YAP, and N-Cadherin protein in tumor tissues analyzed by immunohistochemistry;
scale bar: 50 μm.
B) Representative images showing that tumor tissues are negative for the expression of
aromatase, inhibin, Keratin 20 (KRT20), PAX2, E-Cadherin, and CA125; scale bar: 50 μm.
C) Representative picture showing tumor tissues are negative for PAS stain; scale bar: 50
μm.
D) Representative images showing nuclear p53 expression in tumors derived from
HGrC1-YAPS127Ap53R175H and HGrC1-YAPS127Ap53R175HBRCA1-/- cells, but not in tumors
from HGrC1-YAPS127A; scale bar: 50 μm.
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Figure 3-4. YAP induces HGSOC-like tumors with mesenchymal feature from poorly
differentiated granulosa cells.
Western blot analyses showing the expression of WT1, PAX8, Myc, Keratin 7 (KRT7), NCadherin, E-Cadherin, vimentin, p53, YAP, and BRCA1 in cell lines and tumor cells.
Ovsaho cells was used as positive control for HGSOC.
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Figure 3-5. Tumors derived from poorly differentiated granulosa cells genetically
resemble HGSOC.
Tumors derived from granulosa cells exhibits genomic instability as women’s HGSOC.
aCGH analysis results showing DNA copy number changes of tumors formed by HGrC1YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells, as well
as control cells (HGrC1-CTL). The y axis represents gain (positive, blue) or loss (negative,
red) of copy number, while the x axis represents each chromosome. Tumors from HGrC1YAPS127Ap53R175HBRCA1-/- cells showing the most severe genomic instability.
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Table 1. Primers for PCR.
Gene Name

Primers

Human
HBEGF

F: GCTCCCTCCTGCATCTGCCA
R: GAGGCTCAGCCCATGACACCTCT

CYP19A1

F: TGAATATTGGAAGGATGCACAGAC
R: TGGAATCGTCTCAGAAGTGTAACGAG

CYP11A1

F: TGGGTCGCCTATCACCAGTAT
R: CCACCCGGTCTTTCTTCCA

FSHR

F: TTCAAGAACAAGGATCCATTCC
R: CCTGGCCCTCAGCTTCTTAA

LHCGR

F: TCAATGTGGTGGCCTTCTTCATA
R: TTGGCACAAGAATTGATGGGATA

INHA

F: GTCTCCCAAGCCATCCTTTT
R: TGGCAGCTGACTTGTCCTC

INHBB

F: ATCAGCTTCGCCGAGACA
R: GCCTTCGTTGGAGATGAAGA

INHBA

F: CTCGGAGATCATCACCGTTTG
R: CCTTGGAAATCTCGAAGTGC

PLIN2

F: TCAGCTCCATTCTACTGTTCACC
R: CCTGAATTTTCTGATTGGCACT

MYC

F: CCTACCCTCTCAACGAC
R: ATCTTCTTGTTCCTCCTCAG

TERT

F: GCCTGAGCTGTACTTTGTCAA
R: CGCAAACAGCTTGTTCTCCATGTC

YAP

F: GCAACTCCAACCAGCAGCAACA
R: CGCAGCCTCTCCTTCTCCATCTG

CTGF

F: ACCTGTGGGATGGGCATCT
R: CAGGCGGCTCTGCTTCTCTA

AREG

F: TGGAAGCAGTAACATGCAAATGTC
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R: GGCTGCTAATGCAATTTTTGATAA
GAPDH

F: CAGCCTCAAGATCATCAGCA
R: GTCTTCTGGGTGGCAGTGAT

Mouse
Hsd3b1

F: ACTGCAGGAGGTCAGAGCT
R: GCCAGTAACACACAGAATACC

Hbegf

F: ATGAAGCTGCTGCCGTCGGT
R: TCAGTGGGAGCTAGCCACGC

Ctgf

F: CCCGCCAACCGCAAGATT
R: AGGCGGCTCTGCTTCTCCA

Areg

F: AATGAGAACTCCGCTGCTAC
R: CCCCTGTGGAGAGTTCACTG

Yap

F: CCCGACTCCTTCTTCAAGC
R: CTCGAACATGCTGTGGAGTC

Gapdh

F: CCCTTCATTGACCTCAACTA
R: CCAAAGTTGTCATGGATGAC
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Table 2. Antibodies
Antibody
YAP
Phospho YAP
LATS1
Phospho LATS1
LATS2
Phospho ERK1/2
Phospho CREB
Phospho AKT
Cleaved Caspase 3
Vimentin
Snail
Slug
ZO-1
Erbb3
E-cadherin
N-cadherin (WB)
N-cadherin (IHC)
Myc (WB)
Myc (IHC)
Aromatase (rabbit, IHC)
Aromatase (mouse, WB)
3β-HSD
P450scc
p53 (rabbit, IHC)
p53 (mouse, IF, WB)
BRCA1

Vendor
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Abcam (Cambridge, MA, USA)
Cell Signaling (Danvers, MA, USA)
Abcam (Cambridge, MA, USA)
Cell Signaling (Danvers, MA, USA)
Bio-Rad (Hercules, CA, USA)
Ian Mason, Ph.D. (Dallas, TX, USA)
Millipore (Danvers, MA, USA)
Santa Cruz (Dallas, TX, USA)
Agilent Technologies (Santa Clara, CA, USA)
Santa Cruz (Dallas, TX, USA)
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Keratin 20
PAX8
PAX2
WT1
Inhibin beta A
CA125
KI67
β-Actin
β-Tubulin

Cell Signaling (Danvers, MA, USA)
Proteintech (Rosemont, IL, USA)
Proteintech (Rosemont, IL, USA)
Cell Signaling (Danvers, MA, USA)
Abcam (Cambridge, MA, USA)
Abcam (Cambridge, MA, USA)
Abcam (Cambridge, MA, USA)
Sigma-Aldrich (St. Louis, MO, USA)
Sigma-Aldrich (St. Louis, MO, USA)
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